261510402sasikumar R

FORMULATION DEVELOPMENT AND EVALUATION OF TASTE
MASKED CHEWABLE TABLET 0F SILDENAFIL CITRATE
Dissertation submitted to
THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY,

CHENNAI-600032
In partial fulfillment of the requirements for the award of the degree of
MASTER OF PHARMACY
IN
PHARMACEUTICS
By
R.Sasikumar
(REG NO: 261510402)
Under the guidance of

Mr.V.Sivakumar. M.Pharm, (Ph.D)
Department of Pharmaceutics
DEPARTMENT OF PHARMACEUTICS,
ARULMIGU KALASALINGAM COLLEGE OF PHARMACY,
ANAND NAGAR, KRISHNANKOIL – 626 126
OCTOBER – 2017.
CERTIFICATE
This is to certify that the investigation described in the dissertation entitled
“FORMULATION DEVELOPMENT AND EVALUATION OF TASTE
MASKED CHEWABLE TABLET OF SILDENAFIL CITRATE” submitted by
Reg.No:261510402 was carried out in the Department of Pharmaceutics, Arulmigu
Kalasalingam College of Pharmacy, Anand Nagar, Krishnankoil-626 126, which
is affiliated to The Tamil Nadu Dr. M.G.R. Medical University, Chennai, under the
supervision and guidance of Mr.V.Sivakumar M.Pharm.,(Ph.D) Associate
Professor, Department of Pharmaceutics for the partial fulfillment of degree of
MASTER OF PHARMACY in PHARMACEUTICS.
Place: Krishnankoil Dr.N.Venkateshan. M.Pharm., PhD.,

Date: Principal
Arulmigu Kalasalingam College of Pharmacy.
Anand Nagar, Krishnankoil-626 126.
CERTIFICATE
This is to certify that this investigation described in the dissertation entitled
MASKED CHEWABLE TABLET OF SILDENAFIL CITRATE ” submitted by
Reg.No:261510402 was carried out in the Department of Pharmaceutics, Arulmigu
Kalasalingam College of Pharmacy, Anand Nagar, Krishnankoil-626 126, which
is affiliated to The Tamil Nadu Dr. M.G.R. Medical University, Chennai, under my
supervision and guidance for the partial fulfillment of degree of MASTER OF
PHARMACY in PHARMACEUTICS.
Place: Krishnankoil Mr.V.Sivakumar M.Pharm., (Ph.D)

Date: Department of Pharmaceutics,
Arulmigu Kalasalingam College of Pharmacy,
Anand Nagar, Krishnankoil-626 126
EVALUATION CERTIFICATE
This is to certify that the dissertation work entitled
MASKED CHEWABLE TABLET OF SILDENAFIL CITRATE” submitted by
Reg.No:261510402 to The Tamil Nadu Dr. M.G.R. Medical University, Chennai, in
partial fulfillment of the requirements for the award of degree of MASTER OF
PHARMACY in PHARMACEUTICS was evaluated by,
Date:
Centre: Arulmigu Kalasalingam College of Pharmacy,
Anand Nagar, Krishnankoil-626 126.
Examiner: 1 Examiner: 2
ACKNOWLEDGEMENT
“TALENT AND CAPABILITIES ARE OF COURSE NECESSARY BUT

OPPORTUNITIES AND RIGHT GUIDANCE ARE TWO VERY IMPORTANT
BACKUPS WITHOUT WHICH NO ONE CAN CLIMB THE LADDER TO
SUCCESS”.
I would like to express our thanks to the founder of our institution

“Kalvivallal Thiru. T. Kalasalingam, B.com for providing us required facilities for
extending a rich. And also I convey thank “llaiyavallal” Dr.K.Sridharan, Ph.D.,
Dynamic Directors Dr.S.Shasianand, Ph.D., Mr.S.Arjunkalasalingam, M.S., and
management of our institution for providing us necessary infrastructure.
I take a step forward to express my deep regards to Dr.N.Venkateshan

M.Pharm., PhD., Principal of arulmigu Kalasalingam College of pharmacy for this
enduring support.
I express my gratitude to my guide Associate. Prof. Mr.V.Sivakumar.

M.Pharm., (PhD) for this valuable guidance.
I warmly acknowledge Mr.M.Murugan, M.Pharm, Department of

Formulation Research and Development, Sai Mirra Innopharm Pvt.Ltd, Chennai.
For this inputs throughout the process of this research and they not only served as
guide but also encouraged and challenged me throughout my academic program. They
never accepted less than my best efforts. I thank them. They exchanged their
interesting ideas, thoughts&made this project easy and accurate.
I express my gratitude to Dr.J. Jeya Anandhi M.Pharm., Ph.D., Head of the

Department of Pharmaceutics, Arulmigu Kalasalingam College of pharmacy for the
valuable guidance during the course of study.
My humble thanks to Dr.S.R.S.Senthilkuamr, M.Pharm.Ph.D., Department

of Pharmaceutics. Mr. J.Anbu raj, M.Pharm, MBA, Department of
Pharmaceutics.
I extend a special thanks to non-teaching staff members of Arulmigu
Kalasalingam College of pharmacy especially Mr.P.Laxmana gurusamy and other
for their help and co-operation. My enormous debt of gratitude can hardly to
colleagues and my juniors. My friends provided many stylistic suggestions and
sustentative challenges to help me improve my presentations and clarify my
Arguments. I am heartily thankful to my best friends. R.Subish, B.Stalin,
M.Thirrupathy, P.Vijayanegendran, R.Kiruthika, P.Kaniga, Devi, P.Inigo,
Sivakami.
Who always stand behind me as shadow and their moral support, faith wisdom
and strength have inspired me to be the best I can be.
LIST OF ABBREVIATIONS
S.NO Abbreviations Expanded Terminology

1. NCE New chemical entity
2. CNS Central nervous system
3. GPCRS G-protein coupled receptors
4. CMT Continuous multipurpose melt Technology
5. GIT Gastro Intestinal Tract
6. IER Ion Exchange Resin
7. FTIR Fourier Transform Infrared Radiation
8. Kg Kilogram
9. Mg Milligram
10. µg Microgram
11. RH Relative Humidity
12. Nm Nano meter
13. C Centigrade
14. Gms Grams
15. Q Quantity
16. Mins Minutes
17. Sec Second
18. Mm Milli meter
19. Gm Gram
20. Ml Milli liter
21. Rpm Rotation per minute
22. PDE Phosphodiesterase
23. UV Ultra Violet
24. CCS Cros Caramellose Sodium
25. PVP Poly Vinyl Pyrolidine
26. % Percentage
27. Fig Figure
28. FDA Food And Drug Administration
29. USP United state pharmacopeia
30. WHO World Health Organization
31. ICH International Conference for Harmonization
32. API Active Pharmaceutical Ingredient
CONTENTS
CHAPTER TITLE PAGE

NO.
1. INTRODUCTION 1
2. LITERATURE REVIEW 23
3. AIM AND OBJECTIVE & PLAN OF WORK 35
40
4. DRUG & EXCIPIENT PROFILE
MATERIALS AND METHODS
5.
• List of materials used
• List of equipments used 62
• Pre -formulation studies
• Analytical methods
• Formulation and preparation of chewable tablet
taste masked
• Evaluation of precompression blend
• Evaluation of tablets, Dissolution study.
• Stability studies
6. RESULT AND DISSCUSSION 78
7. SUMMARY AND CONCLUSION 112
8. BIBLIOGRAPHY 114
CHAPTER I
INTRODUCTION
1.INTRODUCTION
1.ORAL SOLID DOSAGE FORMS
A solid dosage form is drug delivery system that includes tablets, capsules,
sachets and pills as well as a bulk or unit-dose powders and granules. Among the
various dosage forms oral solid dosage forms have greater importance and occupy a
prime role in the pharmaceutical market. Oral route of drug administration is widely
acceptable and drugs administered orally as solid dosage form represents the preferred
class of products. Over 90% of drugs formulated to produce systemic effects are
produced as solid dosage forms. Because of these reason when ever New chemical
entity (NCE) has discovered, which shows a sufficient pharmacological action, first
the pharmaceutical company asks whether the drug is successfully administered by
oral route or not. As a natural defence mechanism to prevent infection or dehydration
many trees and shrubs are known to produce an aqueous thick exudation when the
plants bark is injured. Eventually the solution dries up in contract with sunlight and
air and a hard transparent brown-tint glass mass formed. This solid mass is known as
Natural gum1. Excipients play an important role in dosage forms such as tablet,
capsule, lotions, suspensions, syrups and ointments. Plant products serve as an
alternative to synthetic products because of its local accessibility, environment
friendly nature and low prices compared to imported synthetic products2. Plantago
ovata mucilage has been evaluated in fast disintegrating tablet.Ocimum americanum
Linn. Mucilage has been evaluated in disintegrating tablet3. Moringa gum is obtained
from the tree Moringa Oleifera. Which is a water soluble gum extrudes from the bark
on Moringa trees. In present study, an attempt was made to prove Moringa gum as
disintegrant. The oral route of administration still continues to be the most preferred
route due to its manifold advantages including:
1
 Tablets and capsules represent unit dosage forms in which the accurate dose of
drug to show sufficient pharmacological action can be administered. In case of
liquid oral dosage forms such as Syrups, Suspensions, Emulsions, Solutions and
Elixirs the patient is asked to administer the medication of 5-30 ml. Such dosage
measurements are typically error by factor ranging from 20-50 %, when the drug
is self administered by patient.
 Solid dosage forms are less expensive to shipping and less prone for the
degradation when compared to liquid dosage forms4.
1.1.TABLETS
In 1843, the first patent for a hand operated device used to form a tablet was
granted. Tablets are defined as solid preparations each containing a single dose of one
or more active ingredients and obtained by compressing uniform volumes of particles.
They are intended for oral administration, some are swallowed whole, some after
being chewed. Some are dissolved or dispersed in water before being administered
and some are retained in the mouth, where the active ingredient “liberated”. Tablets
are used mainly for systemic drug delivery but also for local drug action. For systemic
use drug must be released from tablet that is dissolved in the fluids of mouth, stomach
and intestine and then absorbed into systemic circulation by which it reaches its site of
action. Tablets remain popular as a dosage form because of the advantages, afforded
both to the manufacturer [e.g. simplicity and economy of preparation, stability and
convenience in packing, shipping and dispensing] and the patient [e.g. accuracy of
dosage, compactness, portability, blandness of taste and ease of administration].
They may differ greatly in size and weight depending on the amount of drug
substance present and the intended method of administration. They may have lines or
break-marks and may bear a symbol or other markings. Tablets may be coated.
2
1.1.1. Advantages of Tablets
The primary potential advantages of tablets are,
 They are the unit dosage forms, which offer the great capabilities of all oral
dosage forms for the greatest dose precision and the least content variability.
 The cost is lower of all oral dosage forms.
 They are the lightest and most compact of all.
 They are in general the easiest and cheapest to packaging and shipment.
 Product identification is potentially the simplest and cheapest, requiring no
additional processing steps when employing an embossed or monogrammed
punch face.
 They may provide the greatest case of swallowing with the least tendency for
hang up above the stomach, especially when coated, provided the tablet
disintegration is not excessively rapid.
 They lend themselves to certain special profile products, such as enteric or
delayed release products.
 They are better suited to large scale production than with other unit oral dosage
forms.
 They have the best combined properties of chemical, mechanical and
microbiological stability of all the oral forms.
1.1.2. Disadvantages
In spite of all these advantages, tablet also possesses some disadvantages. The
disadvantages of tablets include the following
 Some drugs resist compression in to dense compacts, owing to their
amorphous nature or flocculent, low density character.
3
 Drugs with poor wetting properties, slow dissolution properties, intermediate
to large dosages, optimum absorption high in the GIT or any combination of
these features may be difficult or impossible to formulate and manufacture as
a tablet that will still provide adequate or full drug bioavailability.
 Bitter tasting drugs, drug with obnoxious odor or drugs that are sensitive to
oxygen or atmospheric moisture may require encapsulation / entrapment prior
to compression / coating4, 5, 6.
1.1.3. PRINCIPLES OF DOSAGE FORM DESIGN
Drugs are rarely administered slowly as pure chemical substances, but are
almost given as formulated preparations. The principle objective of dosage form
design is to achieve a predictable therapeutic response to a drug included in the
formulation. Before a drug substance can be successfully formulated in to a dosage
form, many factors must be considered. These factors can be broadly grouped in to
three categories.
 Biopharmaceutical considerations (Factors affecting absorption of drugs)
 Drug related factors (Physical and chemical properties of a drug)
 Therapeutic considerations (Disease to be treated and patient factors)
Among various orally administered dosage forms (tablets, capsules, syrup,
solution etc), the tablet dosage form is the most widely used.7, 8
Compressed tablets are defined as solid dosage forms made by compaction of the
formulation containing the drug and certain fillers or excipients selected to aid in the
processing and properties of the drug product.
4
1.2.1 CLASSIFICATION OF TABLETS
I. Classification based on mode of administration.
1) Chewable tablets
2) Tablets to be swallowed
3) Tablets used in oral cavity
 Buccal tablets
 Sublingual tablets
 Troches and lozenges
 Dental cones
1)Tablets administered other than oral route
 Implants
 Vaginal tablets / suppositories
II. Classification based on drug manufacturing process.
1) Standard compressed tablets
2) Multiple compressed tablets
 Compression-coated tablets
 Layered tablets
1) Coated tablets
2) Molded tablets (Tablet triturates)
III. Classification based on drug release profile.
1) Fast dissolving tablets
2) Immediate release tablets
3) Controlled Release tablets (Sustained Release Tablets)
4) Delayed Release tablets (Enteric coated tablets)
5
IV. Tablets used to prepare solutions.
 Effervescent tablets.
 Dispersible tablets.
1.2.2. CHEWABLE TABLET
Chewable tablets which are required to be broken and chewed in between the
teeth before ingestion. These tablets are given to the children who have difficulty in
swallowing and to the adults who dislike swallowing.9
These tablets are intended to disintegrate smoothly in mouth at a moderate rate
either with or without actual chewing, characteristically chewable tablets have a
smooth texture upon disintegration, are pleasant tasting and leave no bitter or
unpleasant taste. Successful tablet formulation development involves the careful
selection of ingredients in order to manufacture a robust solid dosage form. Choosing
the appropriate excipient to perform a specific function in a tablet formulation such as
disintegration or lubrication can be critical to achieving acceptable manufacturing
performance. Sweeteners, both naturally occurring and synthetic are one type of
functional excipient commonly used in chewable tablet formulations to mask the

10,11
unpleasant tastes and facilitate pediatric dosing. Ideally upon chewing, they are
broken down in the mouth and release their ingredients in the process and therefore,
do not have much lag time as required for the disintegration of tablets before
12
absorption from stomach. Chewable tablets are often employed when the active
ingredient is intended to act in a localized manner rather than systemically.
Chewable tablet is one that is palatable and may be chewed and ingested with
little or no water. Manufacturing of chewable tablet is generally done using either wet
granulation process or direct compression. Increasingly, micronized and submicron
6
forms of therapeutically and physiologically active substances are incorporated into
tablet formulation to take advantage of the enhanced absorption characteristics of

13
these forms. They are also used in the administration of antacids and carminatives.
Mannitol is widely used as an excipient in chewable tablet for its non-hygroscopic
nature for moisture sensitive drugs. As we know difficulty in swallowing (Dysphasia)
is common among all age groups, especially in elderly and in also seen of swallowing
of conventional tablets and capsules. Geriatric and pediatric patients and travelling
patients who may not have ready access to water are most need of easy swallowing
dosage forms like chewable tablets. The composition of chewable tablet consists of
gum core, which may or may not be coated. The core is composed of an insoluble
gum base like fillers, waxes, antioxidants, sweeteners, flavouring agents. The
percentage of gum base varies from 30-60% depending upon the base used and its
properties. A flavouring agent is included to make it more palatable.
1.2.3 Advantages of chewable tablets14, 15
Chewable tablets are generally chewed in the mouth prior to swallowing and
are not expected to swallow intact. The main purpose of a chewable tablet is to
provide proper unit dosage forms of medication which can easily to administer to
children or to the elderly who have difficulty in swallowing a tablet intact. The
chewable tablet has some specific advantages.
 Better bioavailability through by passing disintegration (increase dissolution).
 Improved patient acceptance (especially pediatric) through pleasant taste patient
convenience, need no water for swallowing.
 Possible to use as a suitable for liquid dosage forms where rapid onset of action
is needed adsorption of the drug is faster product distinctiveness through
marketing perspective.
7
 The large size of the dosage forms is difficult to swallow.
 In such case, chewable tablets offer effectiveness of therapeutic agent is
improved by the reduction in size that occurs during mastication of tablets
before swallowing.
1.2.4 Disadvantages of chewable tablets
There are of course some limitations to the use of chewable having bad tasting
drug and extremely high dose level.
 It contains sorbitol which causes diarrhea and flatulence flavoring agents present
in a chewable tablet may cause an ulcer in the oral cavity.
 Prolonged chewing of chewable tablets results in pain in facial muscles.
 They are hygroscopic in nature, so must keep in a dry place they slow the
fragile, effervescence granules property. Since they tablets having insufficient
mechanical strength. So careful handling is required.
1.2.5. METHOD OF MANUFACTURING 16, 17, 18
The chewable tablets were prepared by using the following method.
1. Non-aqueous granulation/dry granulation.
2. Aqueous granulation/wet granulation
3. Direct compression.
 Granulation
Granulation is the process in which primary powder particles are made to adhere
to form larger, multi-particles entities Called granules. Pharmaceutically granules
have a size range between 0.2 to 4.0 mm .granulation is used to improve flow and
compressibility of the powders and segregation of the blend compounds. Granulation
is mainly done by using two techniques.
8
1. Dry granulation
It is a novel method for semi-automatic production of granules. the method is
applicable to any solid dosage for pharmaceuticals products.dry granules method
replace existing solid dosage form development and manufacturing technology
offering more rapid. in the process, the powder mixture is compressed without the use
of heat and solvent. two methods are used for dry granulation. The more widely used
slugging where the powder is recompressed and resulting tablet is milled to yield the
granules.
2. Wet granulation
Wet granulation is the most commonly used granulation method. This process
involves wet massing powder blend with a granulating liquid, wet sizing, and drying.
It can be removed from the volatile materials. That it can be removed drying and most
be Non-toxic in nature. The typical liquid includes water, ethanol and isopropyl
alcohol. in this traditional wet granulation method, the wet mass is forced through the
sieve to produce wet granules which are subsequently dried.
3. Direct compression
Direct compression is the most popular choice because it provides the shortest.
Most effective and least complex to produce tablets. This method has mainly used a
group of ingredients can be blended. This is more suitable for moisture and heat
sensitive API’s since it eliminates wetting and drying steps and increases the stability
of active ingredient by reducing to detrimental (Harmful) effects. In the process of
API mixed with the excipients and lubricants, followed by compression.
9
1.2.6. Mechanism of action of chewable tablets19, 20
Chemoreceptor’s on the tongue
Taste is brain interpretation of chemicals triggers on the tongue. This is on
taste buds. Molecules interact with taste receptors on the tongue to taste sensation
.This sensation is the result of signal transudation from the receptor organs for taste,
commonly known as taste buds. These taste buds contain very sensitive nerve
endings, when there dissolve in the saliva. Which produce and transmit an electrical
impulse to the seventh, ninth, tenth to the area of the brain.
Figure no.1. Taste buds in cell Structure
1.2.7. PHYSIOLOGY OF TASTE
The sense of taste is mediated by taste bud, which is a group of taste receptor
cell (50-100 cells), bundled in a cluster like bannans and gives a sensation of taste via
sensory neurons to central nervous system (CNS) in the brainstem. Taste buds are
chemoreceptor stimulated by chemicals dissolved in saliva from oral ingested
medicaments and enter via the taste pore followed by interaction with surface proteins
known as taste receptors causing electrical change within taste cells, which cause the
transmission of signals to the brain.

Four fundamental sensations of the taste have been described.
1. Sweet. (Sugar, glycerol)
2. Salty. (Sodium)
3. Bitter. (Quinine, nicotine)
4. Sour. (Acidic substance)
1. SALTY TASTE (EDGE, UPPER PORTION)
Salty taste is one of the four receptors of the tongue; they are located on the
edge and upper front portion of the tongue.
2. SWEET TASTE (TIP)
The sweet taste is one among the four taste receptors in the tongue. There are
found on tip of the tongue.
3. SOUR TASTE (ALONG SIDES IN BACK)
The sour taste is also one of the four taste receptors of the tongue. They occur
at sides of the tongue and are stimulated mainly by acids.
4. BITTER TASTE (BACK) 21
The bitter taste is the last and one of the four taste receptors on the tongue.
That is located towards the back of the tongue. It is stimulated by a variety of
chemicals substances, most of which are organic compounds, although some
inorganic compounds such as magnesium and calcium also produce bitter sensations.
Figure no.2. Taste buds

1.3. TASTE SIGNALS PATHWAYS 22
Taste transduction begins with the interaction on the taste. (eg. medicine,
food) with taste receptors cells in taste buds. The tastant binds with g-protein coupled
receptors (GPCRS) cells triggering the release of the G-protein called gustducin.the
process of taste sensation begins when gustducin activates the effector enzymes
phosphodiesterase IA (PDE) or phospholipase C BETA-2(PLC).the effectors enzymes
then change the intracellular level second messengers such as cyclic adenosine
monophosphate (CAMP),Inositol, 1,4 ,5 –triphosphate(IP3) and diacylglycerol
(DAG).the second messengers Activate ion channel including calcium channel on the
extra cellular membrane. This ionization depolarizes the cell causing the release of
neurotransmitters that send a nerve impulse to the brain that carries the signal of bitter
taste and taste blockers work by interfering with taste transduction.
Figure no.3. Taste signal pathways
1.3.1. TASTE BLOCKING MECHANISM 23
Taste sensation begins with gustducin activates the effectors enzyme
phosphodiesterase IA (PDE)phospholipase C beta-2(PLC).the effectors enzyme then
change the intracellular level of second messengers such as cyclic adenosine
monophosphate (cAMP)1,4,5-triphosphate (IP3)and diacylglycerol(DAG).the second
messengers active calcium ion channel inside the cell neurotransmitters to the nerves.
Impulse transmits into the brain bitter taste and taste blockers work by interfering
with taste transduction.
Figure no.4. Taste blocking mechanism
1.3.2. TASTE MASKING TECHNOLOGY
Taste masking is defined as perceived reduction of an undesirable taste that
would otherwise exist. 24Methods commonly used for the two types.
1. The chemical method that prevents from the interaction of taste buds with drugs.
2. Physical method.
1.3.3. TWO APPROACHES BASED ON THE BAD TASTE OF THE DRUG
1. By reducing the solubility of drug in the PH of the saliva (5.6-6.8)
2. By altering the affinity and nature of drug will interact with receptors.25
1.3.4. AN IDEAL TASTE MASKING PROCESS AND FORMULATION
SHOULD HAVE THE FOLLOWING PROPERTIES
1. Involve the least number of equipment and process.
2. Effectively mask the taste with as few Excipients .which are economically and
easily available.
3. No adverse effect on the drug bioavailability.

4. Least manufacturing cost.
5. Can be carried out room temperature.
6. Require excipients that have a high margin of safety.
7. Rapid and easy to prepare.
1.3.5. FACTORSCONSIDERATION DURING THE TASTE MASKING
FORMULATION PROCESS INCLUDES
1. The extent of the bitter taste of the API.
2. Required dose load.
3. Drug particulate shape and size distribution.
4. Drug solubility and ionic characteristics.
5. Required disintegration and dissolution rate of the finished product.
6. desired bioavailability.
7. Desired release profile.
8. Required dosage forms.
1.3.6. TASTE MASKING TECHNOLOGIES26
To achieve the goal of taste abatement of the bitter or unpleasant taste of the
drug. The various methods involved.
1. Taste masking with flavors, sweeteners& amino acids.
2. Taste masking by granulation.
3. Taste masking by Microencapsulation.
4. Ion Exchange Resins.
5. Taste masking by formulation of inclusion complexes.
6. Taste masking by Prodrug approach.
7. Solid dispersion system.
14
8. PH Modifiers.
9. Taste masking by adsorption.
10. Taste masking by relation.
11. Multiple Emulsions.
12. Development of Liposome.
13. Miscellaneous taste masking approaches
• By effervescent agents
• Rheological modification
• Continuous multipurpose melt (CMT) Technology
1.Tastemaskingwithflavours,sweetners,andaminoacids
This technique is simplest approach taste masking. But this technique was not
very successful for highly bitter taste drugs taste masking failure. Artificial
sweeteners and flavors are generally being used alone with other taste masking
techniques to improve the efficiency of taste.
A.)Flavors
1.) Complementary to existing of the flavor of the drug.
2.) The known popularity of particular flavors.
3.) Allergy
4.) Age of patients.
Natural vs. synthetic:
 Cheaper.
 More readily available.
 Less variable in chemical composition.
 More stable flavoring agents for taste masking.
15
Natural flavors : Raspberry juices; Liquorices.
Extract : lemon orange spirits
Syrup : ginger tinctures: anise cinnamon aromatic.
Water : peppermint lemon aromatic oils.
Synthetic flavors : alcoholic solution: aqueous solutions: powders
B.)Sweeteners
1. Complement flavors associated with sweetness
2. Soothing flavors associated with the throat.
Natural sweetener - sucrose, glucose, fructose, mannitol.
Artificial sweeteners - saccharin, saccharin sodium, aspartame.
Nutritive sweeteners - sucrose, fructose, glucose.
Non-nutritive sweeteners- Aspartame, sucralose, Neotame, Saccharine.
Polyols - mannitol, sorbitol, xylitol, maltitol.
Novel sweeteners - Trehalose, tagatose.
C. Amino acids
Amino acids and they're (alanine, taurine, glutamic acid, glycine) in
combination with bitter drugs reduce the drug. Ampicillin improved markedly by
preparing its granules with them with an additional quantity of glycine, sweeteners,
flavors and finally compressing them into tablets.
2. Taste masking by granulation
Granulation is a less expensive, rapid operation and an easily scalable taste
masking technology. This step can be exploited as a mean for taste masking of
slightly bitter tasting drug. Granulation lowers the effective surface area of the bitter
substance that come in contact with the tongue upon oral intake. Liquid and low
16
melting point waxes such as glycerol palmitostearate, glyceryl behenate and
hydrogenated castor oil are commonly used ingredients during the granulation to
achieve taste masking.
3. Taste masking by microencapsulation
Microencapsulation is a process by which very tiny droplets or particles of
liquid or solid material are surrounded or coated with a film or polymeric material.
Coating is an extremely useful technique for a number of applications in
pharmaceutical field. Although it is used primarily for production of sustained release,
Gastro-intestinal dosage forms, it also has major applications in masking the
unpleasant taste. It is important to understand that only soluble portion of the drug can
generate the sensation of taste. Coating the active drug with a properly selected
polymer film can reduce its solubility in saliva and thus taste could be masked.
Coating the drug particles created a physical barrier between the drug and the taste
buds and taste of active could be masked. The goal of Microencapsulation may be
accomplished by any of the following techniques.
• Air suspension coating
• Spray drying and spray congealing
• Coacervation - phase separation
• Solvent evaporation
• Multiorifice - centrifugal process
• Pan coating
• Interfacial polymerization
Polymers used for coating in microencapsulation
Coating is an extremely useful technique for number of applications in the
pharmaceutical field. It is classified based buds. Cyclodextrin is most widely used
17
complexing agent for inclusion type complexes. It is sweet, non toxic, cyclic
oligosaccharide obtained from starch. The following are the examples of drugs that
the bitter taste can be suppressed by making inclusion complexes.
4. Ion exchange resins
Ion exchange resins (IER) have received considerable attention from
pharmaceutical scientists because of their versatile properties as drug delivery
vehicles. In past few years, IER have been extensively studied in the development of
Novel drug delivery system and other biomedical applications. Several ion exchange
resin products for oral and peroral administration have been developed for immediate
release and sustained release purposes. Bitter tasting drugs can be absorbed onto ion
exchange resins, thus effectively removing them from solution during the transit
through the mouth, at salivary pH 6.8, remains in intact form making the drug
unavailable for the taste sensation. Various studies have revealed that ion exchange
resins are equally suitable for drug delivery technology. Some ion exchange resins
used widely for taste masking purpose in industries are Amberlite IRP64, Amberlite
IRP69, Indion 204, Indion 214, Kyron T-114 and Kyron T-104.
5. Taste masking by formulation of inclusion complexes
Inclusion complexation is a process in which the guest molecule is included in
the cavity of a host or complexing agent. The complexing agent is capable of masking
bitter taste of drug by either decreasing its oral solubility on ingestion or decreasing
the amount of drug particles exposed to taste.
6. Taste masking by prodrug approach
Chemical modification, including prodrug design is an effective method for
reducing solubility, and thereby improving taste. A prod rug is chemically modified
18
inert drug precursor which upon biotransformation liberates the pharmaceutically
active parent compound. Bitterness of a molecule may be due to the efficiency of the
taste receptor substrate adsorption reaction, which is related to the molecular
geometry of the substrate. If alteration of the parent molecule occurs by derivative
formation, the geometry is altered, affecting the adsorption constant. Thus the
magnitude of a bitter taste response or taste receptor-substrate adsorption constant
may be modified by changing the molecular configuration of the parent molecule. The
extremely bitter antibiotics have been the focus of much work in reversible drug
modification. Taste masking of drug.’
7. Solid dispersion system
Solid dispersion has been defined as dispersion of one or more active
ingredients in an inert carrier or matrix at solid state prepared by melting (fusion)
solvent or melting solvent method. Recently solid dispersions were introduced as a
taste masking technology. Tsau and Damani (1994) disclosed a drug-polymer matrix
composition to achieve the taste masking of dimenhydrinate. Amine or amide group
of dimenhydrinate can have a physical and chemical interaction with the carboxylic
acid and esters groups of copolymers such as shellac, zein and cellulose acetate
phthalate hydrophobic polymers and long chain fatty acids have been used to achieve
the taste masking by solid dispersion. This approach usually requires a higher
concentration of excipients compared to other taste masking techniques. Natural
polymers such as shellac and zein, and enteric polymers like derivatives of acrylic
acid polymers and phthalate are good choices to develop the taste masked solid
dispersions.
19
8. Ph modifiers
Many natural and synthetic polymers, resins and waxes alone or in
combinations have been employed for taste masking. The enteric polymers like
eudragit L are used for taste masking but the pH of saliva is near 5.8 and these
polymers solubilize at pH beyond 5.5 so there is a possibility of drug being partially
leached. Therefore there is a need for the development of taste masking polymer such
that the bitter taste is completely masked by the polymer at the pH of saliva in mouth
and in the reconstitution medium as in case of the liquid orals and further which is
able to protect the drug in a biologically active form, from the moisture in the dosage
form and releasing the drug rapidly in the stomach without affecting its absorption
and bioavailability. Developed to supply these drugs to the oral cavity for buccal,
sublingual, and gingival absorption. The formulation contains the drug in combination
with effervescent agent to promote their absorption in the oral cavity and to mask
their bitter taste. An additional pH adjusting substance was also included in fentanyl
formulation for further promotion for absorption.
9. Taste masking by adsorption
Adsorbates are commonly used in taste masking technologies. Adsorbate of
bitter tasting drug can be considered as the less saliva soluble versions of these drugs.
Adsorption involves preparing a solution of the drug and mixing it with an insoluble
powder that will absorb the drug, removing the solvent, drying the resultant powder,
and then using these dried adsorbates in the preparation of the final dosage form.
Many substrates like veegum, bentonite, silica gel and silicates can be used for the
reparation of Adsorbate of bitter drugs. The bitter taste of ranitidine is masked by
forming an adsorbate with a synthetic cation exchange resin.
20
10. Taste masking by gelation
Water insoluble gelation on the surface of tablet containing bitter drug can be
used for taste masking. Sodium alginate has the ability to cause water insoluble
gelation in presence of bivalent metal ions. Tablet of amiprolose hydrochloride have
been taste masked by applying a undercoat of sodium alginate and overcoat of
calcium gluconate. In presence of saliva, sodium alginate reacts with bivalent calcium
and form water insoluble gel and thus taste masking achieved.
11. Multiple emulsions
A novel technique for taste masking of drugs employing multiple emulsions
has been prepared by dissolving drug in the inner aqueous phase of w/o/w emulsion
under conditions of good shelf stability. The formulation is designed to release the
drug through the oil phase in the presence of gastrointestinal fluid.
12. Development of liposome
Another way of masking the unpleasant taste of therapeutic agent is to entrap
them into liposome. For example, incorporating into a liposomal formulation prepared
with egg phosphatidyl choline masked the bitter taste of chloroquine phosphate in
HEPES (N-2-hydroxyetylpiperzine-N’- 2- ethane sulfonic acid) buffer at pH 7.2.
13. Miscellaneous taste masking approaches
• By effervescent agents
Effervescent agents have been shown to be useful and advantageous for oral
administration of drugs and have been employed for use as taste masking agents for
dosage forms that are not dissolved in water prior to administration. A chewing gum
composition of bitter medicament was formulated to supply the medicament to oral
cavity for local application or for buccal absorption. It comprise a chewing base, an
orally administrable medicament, a taste masking generator of carbon dioxide, and
21
optionally a taste bud desensitizing composition (e.g., oral anesthetic such as
benzocaine) and other non active material such as sweeteners, flavoring components,
and fillers. Recently, effervescent tablets of fentanyl and prochlorperazine were
located and dissected from the surrounding tissue and cut proximally. An
ac‐amplifier and an electronic integrator are used to respectively amplify and
integrate the nerve impulses. The peak height of the integrated response is then taken
as the magnitude of response.
• Rheological modification
Increasing the viscosity with rheological modifier such as gums or
carbohydrates can lower the diffusion of bitter substances from the saliva to the taste
buds. Acetaminophen suspension can be formulated with xanthan gum (0.1‐0.2%) and
microcrystalline cellulose (0.6‐1%) to reduce bitter taste. The antidepressant drug
mirtazapine is formulated as an aqueous suspension using methonine (stabilizer) and
maltitol (thickening agent). Maltitol is stable in the acidic pH range of 2 to 3 and
besides masking the unpleasant taste of the drug, it also inhibit its undesirable local
anesthetic effect .
• Continuous multipurpose melt (cmt)technology
The CMT method was developed for the continuous granulation and coating of
pharmacologically active substances. It was concluded that this method could be
successfully applied for taste masking of bitter drug.
1.3.7 Criteria for selection of chewable tablets
Chewable tablets must be chewed before swallowing and typically contain a
combination of colors, flavors, and sweeteners. This tablet form is suitable for
ingredients with neutral or sweet flavor or tablets that contain a large amount contain a
lot of active ingredients that do not lend themselves to being swallowed whole.
22
CHAPTER II
LITERATURE REVIEW
2. LITERATURE REVIEW
S.V.Sai kumar et al., (2010) The aim of this work was to develop and validate
simple, accurate and precise spectroscopic methods (multicomponent, dual
wavelength and simultaneous equations) for the simultaneous estimation and
dissolution testing of ofloxacin and ornidazole tablet dosage forms. The medium of
dissolution used was 900 ml of 0.01N HCl, using a paddle apparatus at a stirring rate
of 50 rpm. The drug release was evaluated by developed and validated spectroscopic
methods. Ofloxacin and ornidazole showed 293.4 and 319.6nm as λmax in 0.01N HCl.
The methods were validated to meet requirements for a global regulatory filing. The
validation included linearity, precision and accuracy. In addition, recovery studies and
dissolution studies of three different tablets were compared and the results obtained
show no significant difference among products44.
B.Sree giri Prasad et al., (2013) The objective of the present study is to develop
chewable tablets containing different pharmaceutical compositions with simple
manufacturing procedures using different excipients. Mannitols, L-HPC 11,
Aspartame, Crospovidone, Crospovidone, Aerosil, and Magnesium Stearate are used
as excipients for effective formulation of anti-asthmatic drug Montelukast.
Montelukast chewable tablets were prepared by both wet granulation and Direct
Compression methods using suitable excipients. The chewable tablets were better
presented using artificial sweetener Aspartame as flavouring agent. A total of eight
formulations were prepared and the granules were evaluated for pre-compression
parameters. The formulated tablets were evaluated for post-compression parameters.
The results showed that all the physical parameters were within the acceptable limits.
I.R spectral studies revealed that there was no interaction between the drug and
23
excipients. The in vitro release study of formulation F7 showed 98.85%drug release at
the end of 30 min. The stability studies for the formulation F7 showed no significant
changes and the study concludes that formulation F7 showed better characteristics of
chewable tablet45.
Bhupendra kumar poudel et al., (2014) The objective of the present study is to
develop chewable tablets containing different pharmaceutical compositions with
simple manufacturing procedures using different excipients. Mannitols, L-HPC 11,
Aspartame, Crospovidone, Crospovidone, Aerosil, and Magnesium Stearate are used
as excipients for effective formulation of anti-asthmatic drug Montelukast.
Montelukast is a selective, orally acting leukotriene receptor antagonist that is used
for the treatment of asthma and seasonal allergic rhinitis. Montelukast chewable
tablets were prepared by Direct Compression methods using suitable excipients. The
chewable tablets were better presented using artificial sweetener Aspartame as
flavouring agent. A total of forteen formulations were prepared and the granules were
evaluated for pre-compression parameters. The formulated tablets were evaluated for
post-compression parameters .The results showed that all the physical parameters
were within the acceptable limits. The in vitro release study of all the formulations
showed good release. The study concludes that aforementioned excipients can be used
to design chewable montelukast sodium tablets46.
V.Anusha et al., (2012) Albendazole chewable tablets were prepared by wet
granulation method. Using two superdisintegrants such as croscarmellose sodium and
sodium starch glycolate. A total of eight formulations were prepared and the granules
were evaluated for precompression parameters such as angle of repose, bulk density,
tapped density, compressibility index and Hausner’s ratio. The formulated tablets
24
were evaluated for diameter, thickness, hardness, weight variation, friability,
disintegration and drug content. The results showed that all the physical parameters
were within the acceptable limits. IR spectral studies revealed that there was no
interaction between the drug and excipients. The in vitro release study of formulation
F8 showed81.03%drug release at the end of 30 min. The stability studies for the
formulation F8 showed no significant change in disintegration time, drug content and
percentage drug release after stored at 40o±2oC/75±5%RH for a period of30 days.
Hence the study concludes that formulation F8 showed better characteristics of
chewable tablet47.
Bharat Parashar et al., (2012) Albendazole is a benzimidazole derivative with broad
spectrum anthelmenthic activity and excellent tolerability. Orally it is rapidly
absorbed and metabolized to sulfoxide and sulfone, which may be responsible for its
anthelmenthic action. Single dose administration of albendazole has produced cure
rates in ascarisis, hookworm and enterobiasis which are comparable to three day
treatment with mebendazole. Albendazole chewable tablets (400 mg) were prepared
by three methods viz. non aqueous granulation, aqueous granulation and direct
compression and were named as NAG, AG and DC respectively. Tablet prepared by
these three methods were evaluated by different parameters such as average weight,
hardness, Carr’s index, tapped density, friability, disintegration, content uniformity
test, in vitro dissolution etc. All the parameters were found within the specifications.
The study on the dissolution profile revealed that product ‘DC’ had faster dissolution
rate while compared to remaining batches and marketed product. Assay values were
within the limits of 90% to 110%48.
25
V.Gopal et al., (2012) various formulations of Loratadine Chewable tablets
containing different pharmaceutical compositions with simple manufacturing
procedures were developed by using different excipients. The excipients used here are
Lactose, Mannitol, Ethyl cellulose, microcrystalline cellulose, Maize Starch, Citric
Acid, Aspartame, Colloidal silicon dioxide, Magnesium Stearate, D & C Yellow No
10 and Raspberry flavour. Oral chewable tablets are the most preferred among the
conventional dosage forms due to its aesthetic appeal and ease of administering to
children, which has entered the market. The chewable tablet was better presented
using artificial sweetener Aspartame and Raspberry flavour as flavouring agent. The
tablets were evaluated for weight variation, hardness, friability; drug content and
mouth feel along with in-vitro dissolution. As per monograph, the chewable tablets
are not required to comply with disintegration test. Wet granulation process using
Mannitol, Lactose, Micro crystalline cellulose (Avicel-CE 15), Ethyl cellulose and
Sweeteners and Flavours were found to be simple and robust method to prepare
chewable tablets49.
M.Rajesh et al., (2012) Albendazole chewable tablets were prepared by wet
granulation method. Using two superdisintegrants such as croscarmellose sodium and
sodium starch glycolate. A total of eight formulations were prepared and the granules
were evaluated for precompression parameters such as angle of repose, bulk density,
tapped density, compressibility index and Hausner’s ratio. The formulated tablets
were evaluated for diameter, thickness, hardness, weight variation, friability,
disintegration and drug content. The results showed that all the physical parameters
were within the acceptable limits. IR spectral studies revealed that there was no
interaction between the drug and excipients. The in vitro release study of formulation
F8 showed81.03%drug release at the end of 30 min. The stability studies for the
26
formulation F8 showed no significant change in disintegration time, drug content and
percentage drug release after stored at 40o±2oC/75±5%RH for a period of30 days.
Hence the study concludes that formulation F8 showed better characteristics of
chewable tablet50.
Mohit kumar et al., (2014) Formulation of chewable tablet of amoxicillin potassium
clavulanate and perform the in vitro bioequivalence study with trying to enhance the
bioavailability of innovator formulation. chewable tablet are given to the adults who
dislike swallowing and to children who difficulty in swallowing and total 10
formulation were made with different concentration of microcrystalline cellulose &
crosscarmellose sodium .the formulation were evaluated for weight
variation,hardness,friability data indicates good mechanical resistance of the tablet.
All tablet disintegrate in between 3-5 min.the optimized the formulation showed good
disintegration time and release profile maximum drug being release marketed
preparation at all time intervals51.
Y. Kranthi Kumar et al., (2014) In this research study the effect drug release of
albendazole chewable tablets has been determined. The drug release is calculated by
using disintegration process which is directly related to with the hardness of tablets.
The tablets are prepared by using three types of granulating methods are non-aqueous
granulation, aqueous granulation and direct compression. The tablets are evaluated by
calculating different parameters such as hardness, friability, disintegration, assay and
in vitro dissolution studies. The % drug release was determined by using U V
spectrophotometry. In the three techniques and the non-aqueous granulation was the
better technique for the formulation of tablets, dissolution rate and % drug release
other than aqueous granulation and direct compression method. So by this we can say
27
the non- aqueous technique is gives immediate drug release by which the drug can be
used at the time of emergency and gives relief to the patient and the chewable tablets
can used for the children easily. The present study was to prepare the chewable
albendazole tablets by granulating techniques i.e. non aqueous granulation, aqueous
granulation and direct compression methods and to compare the drug release profiles
of the tablets with the marketed52.
Swati Jagdale et al., (2010) Levamisole is a synthetic imidazothiazole derivative that
has been widely used in treatment of worm infestations in both humans and animals.
As an anthelmintic, it probably works by targeting the nematode nicotinergic acetyl-
choline receptor. In the market, levamisole tablets are available in the form of tablets.
Geriatric and paediatric patients find it difficult to swallow these tablets. So in order
to avoid this problem, chewable tablets are most pre-ferable. The chewable tablets of
levamisole were prepared by using lactose or mannitol along with sodium starch
glycolate in concentration ratios especially for paediatric use. Sodium saccharin and
vanilla were used as sweeten-ing agent and flavouring agent respectively. From the
disintegration studies, it was observed that the formulation containing 1.6% w/w of
sodium starch glycolate shows minimum disintegration time whereas formulation
having no or less concentration of sodium starch glycolate shows increase in
disintegration time. It was observed that the formulation containing lactose shows less
disintegration time than formulation containing mannitol53.
Huda.i.G et al., (2013) In the present work, chewable dispersible tablets of
Pregabalin were designed by preparing taste masked granulates of Pregabalin with
Eudragit EPO. The tastes masked granulate was prepared by granulation technique in
Rapid Mixer Granulator using Eudragit EPO with a drug: Eudragit EPO ratios 1:0.15,
28
1:0.2, 1:0.25 and 1:0.3 (% w/w). Assay content and In-vitro decomplexation studies
confirmed taste masking of granulate. It was found that maximum taste masking of
drug with Eudragit EPO was noted at a ratio of 1:0.25. Drug release from Drug:
Eudragit EPO complex in salivary pH imparts slight after bitter taste which was
overcome by addition of sucralose during granulation. A study on different flavor is
studied to enhance mouth feel. The prepared batches of tablets were evaluated for
hardness, friability, drug content uniformity and in vitro dispersion time. Based on
acceptable physical characteristic, formulations were tested for in vitro drug release
pattern (in 0.06M Hydrochloride) 54.
O.G .Bhusnure et al., (2015) Chewable tablets which are required to be broken and
chewed in between the teeth before ingestion. These tablets are given to the children
who have difficulty in swallowing and to the adults who dislike swallowing. These
tablets are intended to disintegrate smoothly in the mouth at a moderate rate either
with or without actual chewing, characteristically chewable tablets have a smooth
texture upon disintegration, are pleasant tasting and leave no bitter or unpleasant taste.
Many active pharmaceutical ingredients (API) inherently possess a bitter taste. Nearly
20% of American adults surveyed complained of bad aftertastes or struggling to
swallow when trying to take medication. The most popular oral dosage forms include
liquids, powders, granules, orally disintegrating tablets (ODT), and chewable tablets.
For solid oral dosage forms like orally disintegrating tablets and chewable tablets,
break-lines can be included in the tablet design to adjust dosing. As a result, chewable
tablets has seen an increased interest from the pharmaceutical industry in taste-
masking technologies55
29
K.Khar et al., (2004) Taste is one of the most important parameters governing patient
compliance. Undesirable taste is one of several important formulation problems that
are encountered with certain drugs. Oral administration of bitter drugs with an
acceptable degree of palatability is a key issue for health care providers, especially for
pediatric patients. Several oral pharmaceuticals, numerous food and beverage
products, and bulking agents have unpleasant, bitter‐tasting components. So, any
pharmaceutical formulation with a pleasing taste would definitely be preferred over a
competitor's product and would translate into better compliance and therapeutic value
for the patient and more business and profits for the company. The desire of improved
palatability in these products has prompted the development of numerous
formulations with improved performance and acceptability. This article reviews the
earlier applications and methodologies of taste masking and discusses the most recent
developments and approaches of bitterness reduction and inhibition for oral
pharmaceuticals56.
Vishnumurthy vummaneni et al., (2012) Taste, smell and texture are the important
factors in development of oral dosage forms. Taste is now a factor influencing the
patient compliance and product quality. “The worser the taste of the medication, the
better the cure” an older attitude which now totally changed. Taste masking of
obnoxious drugs has gained the importance as the most of them are administered
orally. This reason is an initiative for the development of various taste masking
technologies by which the characteristics of the dosage form is improved and good
patient compliance is achieved. The main objective of this review is to explore
various methodologies for masking the taste of obnoxious drugs, applications,
evaluation and also the recent trends in taste masking technologies57.
30
Basim Deshmukh et al., (2014) Sildenafil citrate is a pharmacological agent which
has proven useful in treatment of erectile dysfunction, pulmonary arterial
hypertension as well as high altitude motion sickness. Sildenafil citrate exhibits an
absolute bioavaibality of about 40% and is reported to result in maximum observed
plasma concentration of about 30-120 minutes following after oral administration.
Sildenafil citrate exhibits low water solubility,namely 3.5mg/ml. This low water
solubility with its high presystemic metabolism have contributed to its low oral
bioavailability. Thus,there is a need to to improve the bioavailability of sildenafil
citrate. Fast dissolving tablet of sildenafil citrate were prepared with a intention to
gain pre gastric absorption that will eliminate the presystemic metabolism of drug.
Attempts were also made to improve the acqueous solubility of the drug by forming
its nanocrystals. The nanocrystals of sildenafil citrate were formed by
nanoprecipitation technique and were evaluated for particle size and shape by
scanning electron microscopy and were also subjected to DSC and FTIR analysis.This
formed nanocrystals were further considered as API for the fast dissolving tablet. The
formulated F3 formulation(fast dissolving tablet containing cross povidone as
polymer and sildenafil citrate nanocrystals) shows rapid drug release within 2 minutes
as compared to the tablet containing pure drug58.
Aditi Tripathi et al., (2011) Taste is an important parameter in case of drugs
administering orally. Taste masking becomes a prerequisite for bitter drugs to
improve the patient compliance especially in the pediatric and geriatric population.
The problem of bitter taste of drug in pediatric formulations is a challenge to the
formulators in the present scenario. Masking the bitter taste of drugs is a potential tool
for the improvement of patient compliance which intern decides the commercial
success of the product. Two approaches are commonly utilized to overcome the bad
31
taste of the drug. The first includes reduction of drug solubility in the saliva and
second approach is to alter the ability of the drug to interact with taste receptor.
Various methods are available to mask the undesirable taste of the drugs. Some of
them are coating of drug particles, by formation of inclusion complexes, molecular
complexes of drugs with other chemicals, solid dispersions, melting method, micro
encapsulation, prodrugs, mass extrusion methods and ion exchange resins59.
Rushiraj Jani et al., (2016) Sildenafil citrate is one of the most effective agents for
treatment of erectile dysfunction which acts by inhibiting thecGMP-specific
phosphodiesterase type 5. Extensive research work is focused on flash release dosage
forms and especially fast dissolving films are successful to attract pharma-industry
due to ease of preparation and opportunityto extend patent life. Films are widely
acceptable in patients too because of quick onset and user friendliness. Theaim of
present study was to prepare fast dissolving films of sildenafil citrate which provides
product differentiation from other marketed products and also quick disintegration of
highly bitter drug with satisfactory taste masking inoral cavity. Film formulation can
be taken within the pocket and patient can take it without need of water by
simplyputting it on tongue without any grittiness that is frequently found during
disintegration of orodispersible tablets.the formulation will disintegrate within minute
and ultimately provides good bioavailability and quickonset. The IR studiesconfirmed
complete complexation of drug with taste masking resin. Using experimental design,
the preparedformulations were evaluated for in vitro dissolution, solution time and
their physicomechanical parameters mainlytensile strength.60
Hiren Patel et al., (2012) The present study was undertaken to formulate and
evaluate transdermal gel of Sildenafil citrate. Sildenafil citrate is a drug of choice used
32
in the treatment of premature ejaculation disorder. Transdermal gel has gained more
and more importance because the gel based formulations are better percutaneously
absorbed than creams and ointment bases. Therefore, transdermal gel of Sildenafil
citrate was prepared using different polymers such as carbopol 934P containing
permeation enhancer PEG 400 at different proportions. The study encompasses
compatibility studies using FTIR spectra, drug content, viscosity, spreadability, and
pH determination. Further the optimized formulation evaluated by in vitro and ex vivo
diffusion study. Optimized formulation subjected to stability as well as ex vivo study.
The preliminary compatibility studies conducted revealed that there was no
interaction between Sildenafil citrate and excipients. In vitro drug release study was
carried out with Franz diffusion cell using cellophane membrane in pH 7.4 phosphate
buffers as diffusion medium. Formulation batch containing carbopol 934P and PEG
400 permeation enhancer showed 99.20 % drug release at 180 min and 7.98 g.cm /sec
spreadability. Stabilitystudies conducted under accelerated condition were shown
satisfactory results. It was concluded that carbopol gel containing Sildenafil citrate
showed good consistency, spreadability, homogeneity and stability61.
S.B.Ahire et al., (2012) Taste is an important parameter in administering drugs orally
and is a critical factor to be considered while formulating orodispersible, melt in
mouth, buccal tablet and other formulations which comes in contact with taste buds.
Good flavor and texture are found to significantly affect sell of the product.
Undesirable taste is one of the important formulation problems encountered with most
of the drugs. Taste masking technologies offer a great scope for invention and patents.
Several approaches like adding flavors and sweeteners, use of lipoproteins for
inhibiting bitterness, numbing of taste buds, coating of drug with inert agents,
microencapsulation, multiple emulsion, viscosity modifiers, vesicles and liposomes,
33
prodrug formation, salt formation, formation of inclusion and molecular complexes,
solid dispersion system and application of ion exchange resins have been tried by the
formulators to mask the unpleasant taste of the bitter drugs. The present review
attempts to give a brief account of different technologies of taste masking with respect
to dosage form and novel methods of evaluation of taste masking effect62.
34
CHAPTER 3
AIM AND OBJECTIVE
3. AIM AND OBJECTIVE
The main aim and objective of this study is to formulate and evaluate chewable
tablet of taste masking sildenafil citrate.
3.1. REASON FOR SELECTION OF CHEWABLE TABLETS OF TASTE
MASKING SILDENAFIL CITRATE
Clinically selective inhibitor of phosphodiesterase type 5 enzymes (PDE5) is
extensively used for the treatment of erectile dysfunction. Conventional sildenafil
citrate tablet available in the marked are not suitable where onset of action is slow.
Thus chewable tablet achieve high bioavailability and rapid onset of action.
Particularly one that disintegrates and dissolves or disperses in saliva and
administered without need of water. It has unacceptable taste and present study to
formulate the chewable tablet with taste masked. My attempt was made in the present
work to formulate and evaluate chewable tablet of sildenafil citrate.
"Generally, in man, oral administration of the phospho diesterase inhibitors is
the preferred route, being the most convenient and avoiding the disadvantages
associated with intra cutaneous administration. Phospho diesterase inhibitors include
drugs such as Sildenafil Citrate and they are available in the market in form of a film-
coated tablet, wherein, film-coating has to dissolve and tablet has to disintegrate into
granules and further the drug has to release for dissolution in acidic media of stomach.
Normal mouth dispersible tablets release the drug for absorption in oral cavity.
Further Sildenafil is very bitter to taste PDE inhibitors. Hence formulation
development is very critical. Effectiveness of any phospho diesterase inhibitor
formulation will depend upon initial complexation to the extent necessary to bypass
taste buds without detection with the ability to subsequently release the drug from the
35
complex after pH adjustment in digestive tract. Dispersible tablets are the
formulations that elude the process of disintegration that occurs with conventional
formulation, dispersible tablets are formulated to make the drug product bio-available
at a faster rate for immediate action.
In the present study of sildenafil citrate was designed, for the following reasons.
 Sildenafil citrate pure drugs are bitter taste. Ph-modification method. Higher
dosage forms are administered into the chewable tablet form. Prevent from into
the first pass metabolism. High solubility and high permeability.
 Sildenafil citrate is used in the treatment of erectile dysfunction and also used
into the pulmonary hypertension. Sildenafil citrate has a vasodilator properties
resulting in mild and transient decrease in the blood pressure. Quick on set of
action.
MORINGA OLEIFERA:
Moringa oleifera is a small genus of quick growing tree distributed in India.
The stem of the tree exudes a gum which is initially white in colour but changes to
reddish brown or brownish black on exposure to sunlight. It is sparingly soluble in
water but swells in contact with water giving a highly viscous solution. Moringa
oleifera gum Binder and release retardant in tablet. Binders are agents used to
cohesive quality to the material during the production of the tablet. They import
cohesiveness of the tablet formulation. Which ensures that the tablet remain intact
after compression as well as improving the free flowing quality. Binders have been
used as the solution in the formulation and the method of preparation. The choice of a
particular binding agent depends on the binding force required to form the granules
and compatability with the other ingredients particularly the active drug. It is
36
polyuronide consisting of arabinose, galactose and glucoronic acid in the proportion
of 10:7:2, rhamnose is present in traces. It was observed that drug release increased
with increasing proportions of the excipient and decreased proportion of the gum.
Gum was also studied for its disintegrating property. Different batches of tablets were
formulated varying them by quantity of the gum. It was observed that wetting time
decreased with the increase in concentration of gum in formulation.
37
PLAN OF WORK
3.2 PLAN OF WORK
The present work was carried out to formulate development and evaluate the
chewable tablet by taste masking of sildenafil citrate.
 Chewable tablet prepared by direct compression method.
 Mannitol is widely used as excipients in chewable tablet for its non-hygroscopic
nature for moisture sensitive drug.
 Using artificial sweeteners may provide a satisfactory alternative.
 Taste masking method using dried calcium carbonate different concentration ratio.
Taste masking method was performed by Ph-Modification method.
 Adjustment of pH Values: Many drugs are less soluble at pH different from the
pH value of the mouth, which is around 5.9. Solubilization inhibitor, such as
sodium carbonate, sodium bicarbonate, sodium hydroxide, or calcium carbonate,
was added to increase the pH when granules’ including a sildenafil citrate-
dissolved in aqueous medium, the bitter taste of the drug was successfully masked
by a sweetener alone.
 Performing in Drug-Excipients compatibility studies by IR studies.
3.2.1. Physic-chemical evaluation of the chewable tablet.
• Preformulation studies
• Evaluation of blend
• Angle of repose
• Bulk density
• Tapped density
• Compressibility index
• Hausner’s ratio
38
3.2.2. Evaluation of chewable tablet
• Weight variation.
• Hardness
• Friability
• Thickness
• Drug content
• disintegration time
• Wetting time
39
CHAPTER 4
DRUG AND EXCIPIENT
PROFILE
4. DRUG AND EXCIPIENTS PROFILE
4.1 Drug profile.27
4.1.1. Identification:
4.1.1.1. Drug name: sildenafil citrate
4.1.1.2. Structure:
4.1.1.3. Chemical formula : C28H38N6O11S
4.1.1.4. Molecular weight : 666.703g/mol
4.1.1.5. Melting point : 189-190 °C
4.1.1.6. Dose : 25mg, 50mg, 100mg
4.1.1.7. Type : Small molecule
4.1.1.8 .Category : Erectile dysfunction, pulmonary hypertension
4.1.1.9. Description : white to almost white, crystalline powder. It aqueous
solubility is equivalent to 2.6mg sildenafil per ML
at 250c.
4.1.1.10. Route of administration: oral route, Transdermal gel
4.1.1.11. BCS classification : Class-I

4.1.2. Storage: Store below 300c
4.1.3.Mechanism of action: Sildenafil citrate inhibits the cGMP-specific
phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the
corpus cavernosum located around the penis. penile erection during the period of
sexual stimulation is caused by increased penile blood flow resulting from the
relaxation of penile arteries and corpus smooth muscle. This response has mediated
the synthesis of cGMP in smooth muscle cells .cyclic GMP causes smooth muscle
relaxation and increased blood flow into the corpus cavernosum. The inhibition of
phosphodiesterase type 5 (PDE %) by sildenafil enhances erectile function by
increasing the amount of cGMP>90%absorbed with ~40% reaching circulation into
the following first pass metabolism.
4.1.4. Taxonomy:
4.1.4.1. Kingdom : Organic
4.1.4.2. Classes : Phosphodiesterase type-5
4.1.5. Pharmacokinetic profile:-
4.1.5.1. Absorption: - >90% absorbed with ~40% reaching systemic circulation
unchanged following first pass metabolism.
4.1.5.2. Protein binding: 96% Sildenafil appears to be completely metabolized in the
liver to 16 metabolites. Its metabolism is mediated mainly by cytochrome P450
microsomal isozymes 3A4 (major route) and 2C9 (minor route). The major circulating
metabolite, N-demethylated metabolite, has PDE selectivity similar to the parent drug
and ~50% of it's in vitro potency. The N-demethylated metabolite is further
metabolized to an N-dealkylated N, N-de-ethylated metabolite. Sildenafil also
undergoes N-dealkylation followed by N-demethylation of the piperazine ring.
41
4.1.5.3. Half life : - 4hours
4.1.5.4. Metabolism : - Hepatic.
4.1.5.5. Excretion : - lesser extent in the urine (approximately 13% of the
administered oral dose).
4.1.5.6. Adverse effect: - A headache, urinary tract infection, diarrhea, Cardiac
death, myocardial infection.
4.1.5.7. Therapeutic use: - it’s used in the treatment of erectile dysfunction, and
pulmonary hypertension.
4.2. Excipient Profile.
4.2.1. Calcium carbonate28
4.2.1.1. Non-Proprietary Name:-
BP : calcium carbonates (1:1)
JP : carbonic acid calcium salt (1:1)
PHEUR : calcium carbonate
USP : calcium carbonate
4.2.1.2. Synonyms:-
Cali carbons: calcium carbonates (1:1); precipitated carbonate lime;
precipitated chalk;
4.2.1.3. Chemical name:-
Carbonic acid: calcium salt;
4.2.1.4. Empirical formula and molecular weight:-
Caco3, 100.9
42
4.2.1.5. Structure Formula:-
4.2.1.6. Functional category:
Buffering agent, coating agent, opacifiers, tablet binders, tablet diluents,
therapeutic agents.
4.2.1.7. Application in pharmaceutical formulation or technology:-
Mainly used solid-dosage forms of diluents. Dissolution aid in dispersible
tablets.caco3 bulking agents. Tablets sugar coating on opacifier in film coating tablets.
4.2.1.8. Typical properties:-
Density bulk : 0.8kg/cm3
Floability : cohesive
Hardness : 3.0kg/cm3
Refractive index : 1.59
4.2.1.9. Stability and storage conditions:-
Calcium carbonate is stable and should be stored in well-closed containers.
4.2.2. Polyvinyl Pyrolidine k.3029
4.2.2.1. Synonym: - PVP
4.2.2.2. Chemical Name:
POLYVINYL PYROLIDINE K 30
4.2.2.3. Molecular formula: - (-CH (NCH2CH2CH2CO) CH2-) n

4.2.2.4. Structure:-
4.2.2.5. Functional category:-
Clarifying agents; stabilizers
4.2.2.6. Application:-
Clarifying agents; stabilizers; thickeners agent; tablet fillers; dispersants; PVP
of molecular weight 360,000 are often used as the clarifying agent of beer, vinegar,
and grapewine. Used as the fixing liquid for gas chromatography. It is used as a
colloidal stabilizer and clarifying agent for beer clarification. Apply proper amount
according the demands of production. It can be used for pharmacy, aquaculture, and
livestock disinfectant for the sterilization of the skin and mucous.30
4.2.2.7 Storage:-
Keeped in dry place at the room temperature.
4.2.3. Crosspovidone31
4.2.3.1. Non-Proprietary Name:
BP : crospovidone
PHEUR : crospovidone
USP-NF : crospovidone
4.2.3.2. Synonms:-
Crospovidone;crosphopham;crosslinkedpovidone;polyvinylpyrolidone; pvpp;
1-vinyl-2-pyrrolidinone homopolymer.
4.2.3.3. Chemical Name:-
1-ethenyl-2-pyrolidinone homopolymer.
4.2.3.4. Empirical formula and Molecular Weight:-
(C6H9N)>1000000
Tablet disintegrant.
Povidone darkens to some extent on heating at 1500c, with a reduction in
aqueous solubility. It is stable to a short cycle of heat exposure around
110-1300c,steam sterilization of an aqueous solution dose not alter its properties.
Aqueous solution is susceptible to mold growth and consequently require the addition
of suitable preservatives. Povidone may be stored under ordinary conditions without
undergoing decomposition or degradation. However, since the powder is hygroscopic,
it should be stored in an airtight container in a cool, dry place.28

4.2.3.8. Application in pharmaceuticals:-
Since crospovidone is water insoluble tablet disintegrant and dissolution agent
used 2-5%concentration tablet prepared by direct compression or wet and dry –
granulation method. Crospovidone can be used enhance the solubility of the poorly
soluble drug.
4.2.3.9. Description:-
Povidone occurs as a fine, white to creamy-white colored, odorless or almost
odorless, hygroscopic powder. Povidone with K-values equal to or lower than 30 are
manufactured by spray-drying and occur as spheres. Povidone K-90 and higher K-
value povidone are manufactured by drum drying and occur as plates.
4.2.3.10. Incompatibilities:-
Povidone is compatible in solution with a wide range of inorganic salts,
natural and synthetic resins, and other chemicals. It forms molecular adducts in
solution with sulfathiazole, sodium salicylate, salicylic acid, Phenobarbital, tannin,
and other compounds. The efficacy of some preservatives, e.g. Thimerosal, may be
adversely affected by the formation of complexes with povidone.
4.2.4. Cross carmellose sodium
4.2.4.1. Nonproprietary Name: - Croscarmellose sodium
4.2.4.2. Synonyms:-
Ac-di-sol; carmellosum natricum conexum; Crosslinked
carboxymethylcellulose sodium; Explocel: modified cellulose gum; Nymcel ZSX;
Pharmacel XL; Primellose;
Cellulose, carboxymethyl ether.
46
4.2.4.4. Molecular Weight:-
90000-700000
4.2.4.5. Structural Formula:-
4.2.4.6. Functional Category:-
Tablet and capsule disintegrant.
Croscarmellose sodium occurs as an odorless, white or grayish-white powder.
4.2.4.8. Solubility:-
Insoluble in water, although Croscarmellose sodium rapidly swells to 4-8
times its original volume on contact with water. Practically insoluble in acetone,
ethanol, and toluene32
4.2.4.9. Stability and Storage Conditions:-
Croscarmellose sodium is a stable though the hygroscopic material. A model
tablet formulation prepared by direct compression, with Croscarmellose sodium as a
disintegrant, showed no significant difference in drug dissolution after storage at
3000C for 14 months. Croscarmellose sodium should be stored in a well-closed
container in a cool, dry place.

The efficacy of disintegrant such as Croscarmellose sodium may be slightly
reduced in tablet formulations prepared by either the wet-granulation or direct
compression process that contain hygroscopic excipients such as sorbitol.
Croscarmellose Sodium is not compatible with strong acids or with soluble salts of
iron and some other metals such as aluminum, mercury, and zinc.
4.2.4.11. Applications:-
Croscarmellose sodium is used in oral pharmaceutical formulations as a
disintegrant for capsules, tablets, and granules. In tablet formulations, Croscarmellose
sodium may be used in both direct-compression and wet-granulation processes. When
used in wet granulations, the Croscarmellose sodium should be added in both the wet
and dry stages of the process (intra and extra- granularly) so that the wicking and
swelling ability of the disintegrant are best utilized. Croscarmellose sodium at
concentrations up to 5% w/w may be used as tablet disintegrant, although normally
2% w/w is used in tablets prepared by direct compression and 3%w/w in tablet
prepared by wet granulation process.
4.2.4.12. Related Substances: -
Carboxy methyl cellulose calcium: Carboxy methyl cellulose sodium
4.2.5. Mannitol33
4.2.5.1. Nonproprietary Names:-
• BP : Mannitol
• JP : D-Mannitol
• PHEUR: Mannitolum
• USP :Mannitol
48
4.2.5.2. Synonyms:-
Cordycepic acid, E421, manna sugar, D-mannite, mannite, Mannogem,
pearlitol.
4.2.5.3. Chemical Names:-
D-Mannitol
4.2.5.4. Empirical formula and Molecular Weight:-
C6H14O6. 182.17
Diluent, diluents for lyophilized preparations, sweetening agent, tablet and
capsule diluents, tonicity agent.
4.2.5.6. Applications in Pharmaceuticals Formulation or Technology:-
Mannitol is widely used in pharmaceutical formulations and food products. In
pharmaceutical preparations it is primarily used as a diluent (10 – 90% w/w) in tablet
formulations, where it is of particular value since it is not hygroscopic and may thus
be used with moisture-sensitive active ingredients. Mannitol may be used in direct-
compression tablet applications, for which the granular and spray-dried forms are
available, or in wet granulations. Granulations containing mannitol have the
advantage of being dried easily. Specific tablet applications include antacid
preparations, glycerly trinitrate tablets, and vitamin preparations. Mannitol is
commonly used as an excipient in the manufacture of chewable tablet formulations
because of its negative heat of solution, sweetness, and ‘mouth feel’. In lyophilized
preparations, mannitol (20-90% w/w) has been included as a carries to produce a stiff,
homogeneous cake that improves the appearance of the lyophilized plug in a vial. A
pyrogen-free form is available specifically for this use34.
49
Mannitol has also been used to prevent thickening in aqueous antacid
suspensions of aluminum hydroxide (<7% w/v).It has been suggested as a plasticizer
in soft-gelatin capsules, as a component of sustained-release tablet formulations, and
as a carries in dry powder inhalers. It is also used as diluents in rapidly dispersing oral
dosage forms. It is used in food applications as a bulking agent.
Therapeutically, mannitol administered parenterally is used as an osmotic
diuretic, as a diagnostic agents for kidney function,as an adjunct in the treatment of
acute renal failure, and as an agent to reduce intracranial pressure, treat cerebral
edema, and reduce intraocular pressure .given orally, mannitol is not absorbed
significantly from the GI tract, but in large doses it can cause osmotic diarrhea.
Mannitol is D-Mannitol.it is a hexahydric alcohol related mannose and is
isomeric with sorbitol.Mannitol occurs as a white, odourless, crystalline powder, or
free-flowing granules. It has a sweet taste, approximately as sweet as glucose and half
as sweet as sucrose, and imparts a cooling sensation in mouth. Microscopically, it
appears as orthorhombic needles when crystallized from alcohol.
Mannitol is stable in the dry state and in aqueous .solutions may be sterilized
by filtration or by autoclaving and if necessary may be autoclaved repeatedly with no
adverse physical or chemical effects. In solution, mannitol is not attacked by cold,
dilute acids, alkali, or by atmospheric oxygen in the absence of catalysts. Mannitol
does not undergo maillaard reaction. The bulk material should be stored in a well-
closed container in a cool, dry place.
50
Mannitol solutions, 20%w/v or stronger, may be salted out potassium chloride
or sodium chloride. Precipitation has been reported to occur when a 25%w/v mannitol
solution was allowed to contact plastic. Sodium cephapirin at 2 mg/ml and 30 mg/ml
concentration is incompatible with 20% w/v aqueous mannitol solution. Mannitol is
incompatibilities with xylitol infusion and may from complexes with some metals
such as aluminum, copper, and iron. Reducing sugar impurities in mannitol have been
implicated in the oxidative degradation of a peptide in a lyophilized formation.
Mannitol was found to reduce the oral bioavailability of cimetidine compared to
sucrose.
4.2.6. Aspartame35
4.2.6.1 Non-Proprietary Name:-
BP: aspartame
PHEUR: aspartame
USP-NF: aspartame
4.2.6.2. Synonyms:-
(3S)-3-Amino-4-[[(1S)-1-benzyl-2-methoxy-2-oxoethyl] amino]-4-
Oxobutanoic acid; 3-amino-N-(a-carboxyphenethyl) succinamic
Acid N-methyl ester; 3-amino-N-(a-methoxycarbonylphenethyl)-
Succinamic acid; APM; aspartame; aspartyl phenyl amine methyl
N-L-a-Aspartyl-L-phenylalanine 1-methyl ester.
C14H18N2O5 294.30
51
4.2.6.6. Functional category:
Sweetening agents.
4.2.6.7. Application:
Aspartame is used as an intense sweetening agent in beverage products, food
products, and table-top sweeteners, and in pharmaceutical preparations including
tablets,(1,2) powder mixes, and vitamin preparations. It enhances flavor systems and
can be used to mask some unpleasant taste characteristics; the approximate
sweetening power is 180–200 times that of sucrose. Unlike some other intense
sweeteners, aspartame is metabolized in the body and consequently has some nutritive
value: 1 g provides approximately 17 kJ (4 kcal). However, in practice, the small
quantity of aspartame consumed provides minimal nutritive agents36.
4.2.6.8. Description:
Aspartame occurs as an off white, almost odorless crystalline Powder with an
intensely sweet taste.
Density (true) 1.347 g/cm3
Effective angle of internal friction 43.08(3)
Melting point 246–2478C

4.2.6.9. Stability and Storage Conditions:
Aspartame is stable in dry conditions. In the presence of moisture, Hydrolysis
occurs to form the degradation products L -aspartyl-L phenylalanine And 3-benzyl-6-
carboxymethyl-2,5-diketopiperazine with a resulting loss of sweetness. A third-
degradation product is also known, b-L-asparty phenylalanine methyl ester. For the
stability profile at 258C in aqueous buffers.
4.2.7. Aerosil
4.2.7.1. Nonproprietary Names:-
BP: Colloidal Anhydrous Silica
JP: Light Anhydrous Silicic Acid
PhEur: Silica, Colloidal Anhydrous
USP-NF: Colloidal Silicon Dioxide
4.2.7.2. Synonyms:-
Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; colloidal silica; fumed silica;
Fumed silicon dioxide; hochdisperses silicum dioxid; SAS; silica
Colloidalis anhydrica.
Silica
4.2.7.4. Empirical Formula and Molecular weight:-
Sio2 60.08
Adsorbent; anticaking agent; emulsion stabilizer; glidant; suspending agent;
tablet disintegrant; thermal stabilizer; viscosity-increasing agent.
53
4.2.7.6. Application in pharmaceutical Formulation or Technology:-
Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and
food products; Its small particle size and large specific surface area give it desirable
flow characteristics that are exploited to improve the flow properties of dry powders
in a number of processes such as tableting and capsule filling. Colloidal silicon
dioxide is also used to stabilize emulsions andas a thixotropic thickening and
suspending agent in gelsandsemisolid preparations.With other ingredients of similar
refractive index, transparent gels may be formed. The degree of viscosity increase
depends on the polarity of the liquid (polar liquids generally require a greater
concentration of colloidal silicon dioxidethan nonpolar liquids). Viscosity is largely
independent of temperature. However, changes to the pH of a system may affect the
viscosity; In aerosols, other than those for inhalation, colloidal silicon dioxide is used
to promote particulate suspension, eliminate hard settling, and minimize the clogging
of spray nozzles. Colloidal silicon dioxide is also used as a tablet disintegrant and as
an adsorbent dispersing agent for liquids in powders. Colloidal silicon dioxide is
frequently added to suppository formulations containing lipophilic excipients to
increase viscosity, prevent sedimentation during molding, and decrease the release
rate. Colloidal silicon dioxide is also used as an adsorbent during the preparation of
wax microspheres; as a thickening agent for topical preparations; and has been used to
aid the freeze-drying of nanocapsules and nanosphere suspensions.37
Aerosols-concentration 0.5-2.0
Emulsion stabilizer-1.0-5.0
Glidant-0.1-0.5
Suspending agent-2.0-10.0
54
Colloidal silicon dioxide is submicroscopic fumed silica with a particle size of
about 15 nm. It is a light, loose, bluish-white-colored, odorless, tasteless, amorphous
powder.
4.2.7.8. Stability and Storage Conditions:-
Colloidal silicon dioxide is hygroscopic but adsorbs large quantities of water
without liquefying. When used in aqueous systems at a pH 0–7.5, colloidal silicon
dioxide is effective in increasing the viscosity of a system. However, at a pH greater
than 7.5 the viscosity increasing properties of colloidal silicon dioxide are reduced;
and at a pH greater than 10.7 this ability is lost entirely since the silicon dioxide
dissolves to form silicates. Colloidal silicon dioxide powder should be stored in a
well-closed container.38
Incompatible with diethylstilbestrol preparations
4.2.8. Talc
4.2.8.1. Synonyms:-
Altalc, E553b, hydrous magnesium calcium silicate, hydrous magnesium
silicate, Luzenac phrama, magnesium hydrogen metasilicate, Magsil Osmanthus,
Magsil star, powdered talc, purified French chalk,Purtalc, soapstone, superior.
4.2.8.2. Empirical Formula and molecular Weight:-
Talc is purified, hydrated, magnesium silicate, approximating to the formula
Mg6 (Si2O5)4(OH)4. It may contain small, variable amounts of aluminum silicate and
iron. Molecular weight is 260.8617
4.2.8.3. Structural Formula:-
Mg3Si4O10 (OH) 2
55
Anti caking agent, glidant, tablet and capsule diluents, tablet and capsule
lubricant.
4.2.8.5. Applications in Pharmaceutical Formulation or Technology:-
Talc was once widely used in oral solid dosage formulation as a lubricant and
diluents, although today it is less commonly used. However, it is widely used as a
dissolution retardant in the development of controlled-release products. Talc is also
used as a lubricant in tablet formulations, in a novel powder coating for extended-
release pellets, and as an adsorbent. In topical preparations, talc is used as a dusting
powder, although it should not be used to dust surgical gloves. Talc is a natural
material; it may therefore frequently contain microorganisms and should be sterilized
when used as a dusting powder.39
• Dusting powder –concentration (90.0-99.0%)

• Glidant and tablet lubricant-1.0-10.0
• Tablet and capsule diluents-5.0-30.0
Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous,
crystalline powder. It adheres readily to the skin and is soft to the touch and free from
grittiness.
Incompatible with quaternary ammonium compounds.
4.2.9. Starch
4.2.9.1. Non-proprietary Name:-
BP: Maize starch
JP: Corn Starch
PhEur: Maize Starch
4.2.9.2. Synonyms:-
Amido; amidon; amilo; amylum; PharmGel; Eurylon; fecule; Hylon; maydis
amylum; Melojel; Meritena; oryzae amylum;
56
(C6H10O6)nwhere n = 300–1000.
Tablet and capsule diluent; tablet and capsule disintegrant; tabletbinder;
thickening agent.
4.2.9.5. Application in pharmaceuticals
Starch is a versatile excipient used primarily in oral solid-dosageformulations
where it is utilized as a binder, diluent, anddisintegrant.As a diluent, starch is used for
the preparation of standardized triturates of colorants, potent drugs, and herbal
extracts, facilitating subsequent mixing or blending processes in manufacturing
operations.Starch is also used in dry-filled capsule formulations forvolume adjustment
of the fill matrix,and to improve powder flow, especially when using dried starches.
Starch quantities of 3–10% w/w can act as an antiadherent and lubricant in tableting
and capsule filling. In tablet formulations, freshly prepared starch paste is used at a
concentration of 3–20% w/w (usually 5–10%, depending on thestarch type) as a
binder for wet granulation. The required binder ratio should be determined by
optimization studies, using parameters such as tablet friability and hardness,
disintegration time, and drug dissolution rate. Starch is one of the most commonly
used tablet disintegrants at concentrations of 3–25% w/w.
Starch occurs as an odorless and tasteless, fine, white to off-white powder. It
consists of very small spherical or ovoid granules or grains whose size and shape are
characteristic for each botanical variety.
57
4.2.9.7. Stability conditions:-
Dry starch is stable if protected from high humidity. Starch is Considered to be
chemically and microbiologically inert under both amylose and amylopectin have
been evaluated as safe and without limitation for daily intake. Contamination of
surgical wounds with the starch glove powder used by surgeons has resulted in the
development of granulomatouslesions.
4.2.10.8. Incompatibility:-
Starch is incompatible with strongly oxidizing substances. Colored inclusion
compounds are formed with iodine.
4.2.10.9. Safety:-
Starch is an edible food substance, considered a food ingredient and not a food
additive. It is regarded as an essentially nontoxic and nonirritant material. Starch is
therefore widely used as an excipient in pharmaceutical formulations.
4.2.10. Citric acid monohydrate40
4.2.10.1. Non-Proprietary Name:-
BP : citric acid mono hydrate.
JP : citric acid hydrate.
PHEUR: citric acid mono hydrate.
USP : citric acid mono hydrate.
4.2.10.2. SYNONMS:-
Acidum citricum monohydricum; 1, 2, 3 tri carboxylic acid.
2-hydroxy- 1, 2, 3 propanetric carboxylic acid mono hydrate
C6H8O7.H2O 210.14
58
4.2.10.5. Structural formula:-
Acidifying agent; antioxidants; buffering agents; chelating agents; flavoring
agents.
4.2.10.7. Application:-
Widely used in pharmaceutical formulations and food products; primarily
adjust the PH of the solutions. It also used in the experimental for the tablets PH
adjust and also using tablets material in enteric coating tablets in the colon specific
drug delivery systems. Citric acid used in the flavors’ enhancers for it acidic taste.
Citric acid mono hydrate is a loss of water for crystallization in dry air.
When heated at about 400c.it slightly deliquescent in moist air .dilute aqueous solution
of the citric acid may be ferment on standing.41
Citric acid monohydrate is translucent crystals, or white crystalline,
efflorescent powders. It is an odorless and strong acidic taste.
4.2.10.10. Typical properties: -
Density: 1.542g/cm3
Hygroscopicity: AT relative humidity at 250c.the bulk monohydrate
and anhydrous materials at the store at air tight containers and store in cool place.
4.2.10.11. Methods of manufacture:-
Citric acid occurs naturally in a number of plant species and may be
extracted from lemon juice, which contains 5–8% citric acid Pineapple waste.
Anhydrous citric acid may also be produce industrially by mycological fermentation
of crude sugar solutions Such as molasses, using strains of aspergillums Niger. Citric
acid is purified by recrystallization; the anhydrous form is obtained from a hot
concentrated aqueous solution and the monohydrate from a Cold concentrated
aqueous solution.
4.2.11. Magnesium stearate:-
4.2.11.1. Synonyms:-
Magnesium octadecanoate; Octadecanoic acid, magnesium Salt; Stearic
acid, magnesium salt.
Octadecanoic acid magnesium salt.
4.2.11.3. Molecular Formula:-
C36H18N2505
4.2.11.4. Molecular weight:-
591.34
Tablet and capsule lubricant.
4.2.11.6. Application in pharmaceutical Formulation or Technology:-
It is widely used in cosmetics, food and pharmaceutical Formulation. It is
primarily used as a lubricant in capsule in barrier creams. And tablet manufacture at
concentrations between 0.25% and 5.0% w/w.
60
4.2.11.7. Stability and Storage:-
It is stable and should be stored in a well-closed container In a cool, dry place.
Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with
strong oxidizing materials. It cannot be used in products containing aspirin, some
vitamins, and most alkaloid salts.
4.2.11.9. Safety:-
Nontoxic following oral administration. However, oral Consumption of large
quantities may produce a laxative Effect or mucosal irritation.42
61
CHAPTER 5
MATERIALS AND METHODS
5.1 MATERIALS AND METHODS
The Materials used in the present work are as follows.
S NO Materials Name of the supplier
1. Sildenafil citrate Chandra labs, hyd
2. Dried calcium carbonate MYL CHEM MUMBAI
3. Oyster Calcium Carbonate Chandra labs, hyd
4. PvP k30 MYL CHEM Mumbai
5. Crospovidone MYL CHEM Mumbai
6. Croscarmellose sodium MYL CHEM Mumbai
7. Mannitol S.D Fine Chem. LTD Mumbai
8. Aspartame S.D Fine Chem. LTD Mumbai
9. Lemon flavor MYL CHEM Mumbai
10. Peppermint flavor MYL CHEM Mumbai
11. Sunset yellow lake MYL CHEM Mumbai
12. Aerosil S.D Fine Chem. LTD Mumbai
13. Talc MYL CHEM MUMBAI
14. Magnesium stearate Chandra, labs hyd
15. Citric acid monohydrate S.D FINE CHEM.LTD.
62
5.2 MATERIALS AND METHOD
The Materials used in the present work are as follows.
S. NO. Materials Name of the supplier
1. Sildenafil citrate Chandra labs, hyd
2. Dried Calcium carbonate Chandra labs, hyd
3. Moringa gum Local Nursery
4. Aerosil MYL CHEM Mumbai
5. Starch MYL CHEM Mumbai
6. Mannitol S.D Fine Chem. LTD Mumbai
7. Citric acid monohydrate S.D Fine Chem. LTD Mumbai
8. Lemon flavor MYL CHEM Mumbai
9. Peppermint flavor MYL CHEM Mumbai
10. Sunset yellow lake MYL CHEM Mumbai
11. Talc S.D Fine Chem. LTD Mumbai
12. Magnesium strearate MYL CHEM MUMBAI
63
5.3. Equipment
The equipment used in the present work are as follows
S.no Instruments Source
1 Electronic balance Shimadzu japan
2 UV/Visible Spectrophotometer Corporation-BL-220H
3 FTIR spectrophotometer Corporation Japan
4 Dissolution apparatus Shimadzu japan
5 Hot Air Oven Biotech India.
6 Compression machine Cadmach machinery
64
5.1.1. METHODOLOGY
5.1.1.1. Preformulation studies
5.1.1.2. Construction of standard graph of sildenafil citrate in 0.01N HCL.
5.1.1.3. Preparation of 0.01N HCL.
1. Take 8.5ml of Conc.HCl in distilled water and makeup to 10000ml with distilled
Water to get 0.01N HCl43.
2. Construction of standard graph of sildenafil citrate in 0.01n hcl.
3. Preparation of stock solution.
a. The accurately weighed amount of 30 mg was transferred into a 100ml volumetric
flask. And the volume was made up to 50 mL with 0.01N HCl.
4. Preparation of working standard solution.
a. From this stock solution, 2.5,4,5,6,7.5 was taken and diluted to 50 mL with 0.01N
HCl which has given the solution having the concentration of 100 mcg/mL
5. Preparation of serial dilutions for standard calibration curve.
Necessary dilutions were made by using this second solution to give the different
concentrations of sildenafil citrate (2.5,4,5,6,7.5 mcg/mL) solutions.
The absorbance of above solutions was recorded at λmax (290 nm) of the drug
using double beam UV-Visible spectrophotometer. A standard graph was plotted
between the concentration (on X-axis) and absorbance (on Y-axis).
5.2.1. Drug – excipient compatibility study
The IR absorption spectra of the pure drug and with different excipients were
taken in the range of 4000-500 cm-1 using KBr disc method, 1-2 mg of the substance
to be examined was triturated with 300-400 mg, specified quantity, of finely
powdered and dried potassium bromide. These quantities are usually sufficient to give
a disc of 10-15MM diameter and pellet of suitable intensity by hydraulic press. The
65
infrared spectrum of sildenafil citrate was recorded by using FT-IR spectroscopy and
observed for characteristic peak of drug, and undisturbed drug structure of the drug,
which indicates there was no drug.44
5.2.2. Formulation of chewable tablet (direct compression method)
The chewable tablets containing 100mg sildenafil citrate were prepared with a
total tablet weight of 700mg. All the formulations were prepared by direct
compression.45
Procedure
1. Sildenafil citrate and all other ingredients were individually passed through a
sieve no.40.
All the ingredients were mixed thoroughly by triturating up to 15minties.
2. The powder mixture was lubricated with Magnesium stearate. The tablets were
prepared by using direct compression method according to the formulation table.
3. Then the blend was compressed using 13MM Flat beveled edged scored on one
side
66
Table No: 1 Composition of different formulations for chewable tablet by Direct
Compression Method
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9
Sildenafil citrate 143 143 143 143 143 143 143 143 143
Calcium
70 140 210 280 350 -- 350 350 350
carbonate(dried)
Calcium
carbonate(oyster -- -- -- -- -- 350 -- -- --
shell)
PVP k.30 21 21 21 21 21 21 21 21 21
Purified water -- -- -- -- -- -- -- -- --
Crospovidone -- 15 25 30 35 35 -- 35 --
Cros carmellose
-- 15 25 30 35 35 35 -- --
sodium
Micro
Crystalline -- --- --- --- --- --- --- --- 35
Cellulsoe
Aspartame 16 16 16 16 16 16 16 16 16
Lemon flavor 7 7 7 7 7 7 7 7 7
Peppermint
4 4 4 4 4 4 4 4 4
flavor
Sunset yellow
3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5
lake
Mannitol 404 304 214 134 54 54 89 89 89
Aerosil 7 7 7 7 7 7 7 7 7
Talc 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5
Magnesium
7 7 7 7 7 7 7 7 7
stearate
Citric acid
14 14 14 14 14 14 14 14 14
monohydrate
Avg.weight total 700mg 700mg 700mg 700mg 700mg 700mg 700mg 700mg 700mg
67
5.2.3. Chewable tablet (direct compression method)
After the batch was optimized and compared with (F5) and (F6). (F6) was
more compatible with best (F5). (F6) formulation produce tastes masked but grittiness
formed. The optimized batch in both was compressed by using same ingredients but
different calcium carbonate (oyster shell).F7-F9 using super disintegrants like
croscarmellosesodium, crospovidone.
5.2.4. Formulation of chewable tablet (wet granulation method)
The tablets containing 100mg sildenafil citrate were prepared with a total
tablet weight of 700mg. All the formulations were prepared by wet granulation
method.43
5.3.1. Isolation of moringa oleifera gum
The gum was collected from trees (Injured site). It was dried, ground and passed
through sieve no 80. Dried gum (10g) was stirred in distilled water (250ml) for 6-8
hours at room temperature. The supernatant was obtained by centrifugation. The
residue was washed with water and the washings were added to supernatant. The
procedure was repeated four times. Finally the supernatant was made up to 500 ml
and the treated with twice the volume of acetone by continuous stirring. The
precipitated material was washed with distilled water and dried at 50-60ºC under
vacuum.
Figure no.5 Moringa gum

5.3.2. Formulation of tablet
The tablets of sildenafil citrate were prepared by wet granulation method using
Moringa Oleifera gum, dried calcium carbonate as taste masking agent, Starch as
binder, Purified talc and Magnesium Stearate as lubricant and Aerosil as glidant .citric
acid monohydrate as adjust Ph of the solutions. The drug and other ingredients with
half quantity of disintegrant were mixed together, sufficient quantity of starch paste
was added to form coherent mass. The wet mass was granulated using sieve No. 40
and the granules formed were dried into hot Air oven at 40ºC for 20 minutes and
regranulated using sieve no 20. The granules were blended with remaining quantity of
the disintegrant (extra granular disintegrant), purified talc, aerosil and compressed
into 13MM Flat beveled edged scored on one side (Compression machine,
Ahmedabad, India).
69
Table No: 2 Composition of different formulations for wet granulation method
Sr. Ingredients Quantity in mg

No. F10 F11 F12
1. Sildenafil citrate 143 143 143
2. Dried calcium carbonate 350 350 350
3. Moringa gum 4 6 8
4. Starch 15 15 15
5. Citric acid monohydrate 14 14 14
6. Aerosil 4 4 4
7. Lemon flavor 7 7 7
8. Peppermint flavor 4 4 4
9. Sunset yellow lake 3.5 3.5 3.5
10. Mannitol 148.5 146.5 144.5
11. Talc 4 4 4
12. Magnesium strearate 3 3 3
Avg.weight total 700mg 700mg 700mg
5.4.1. EVALUATION OF PRECOMPRESSION BLEND46
• Flow Properties:
• The angle of Repose:
The flow property was determined by measuring the Angle of Repose. In
order to determine the flow property, the Angle of Repose was determined. It is the
maximum angle that can be obtained between the free standing surface of a powder
heap and the horizontal.
Angle of repose= tan-¹ (h/r)
70
Where,
h = height of a pile (2 cm)
r = radius of pile base.
5.4.2. Procedure
• 20gms of the sample was taken
• The sample was passed through the funnel slowly to form a heap.
• The height of the powder heap formed was measured.
• The circumference formed was drawn with a pencil on the graph paper.
• The radius was measured and the angle of repose was determined. This was
repeated three times for a sample.
5.4.3. Bulk density
Bulk density is the ratio of given mass of powder and its bulk volume. Bulk
density was determined by measuring the volume of known mass of powder sample
that has been passed through the screen in to graduated cylinder or through volume
measuring apparatus into the cup.
Bulk density = M / V0
Where M= mass of the powder;
The V0=bulk volume of the powder.
Limits:
It has been stated that the bulk density values having less than 1.2 g/cm3
indicates good Packing and values greater than 1.5 g/cm3 indicates poor Packing.
71
5.4.4. Tapped density
A known quantity of powder was transferred to a graduated cylinder and volume
V0 was noted. The cylinder fixed to a density determination apparatus, tapped for 500 times
than reading was observed. The density is achieved by mechanically tapped by a measuring
cylinder containing the powder sample. After observing the initial volume the cylinder is
mechanically tapped and volume reading was taken until little further volume changes are
observed.
Tap density = M / Vr
Where M = mass of the powder,
Vr = final tapping volume of the powder.
5.4.5. Compressibility index and Hauser’s ratio
The compressibility index and Hausner's ratio may be calculated using
measured values of bulk density and tapped density as follows:
Compressibility index = 100 × tapped density / bulk density
Hauser’s ratio = tapped density / bulk density
Flow properties and corresponding Angle of repose, Compressibility index
and Hauser’s ratio:
72
Table No: 3 ACCEPTANCE CRITERIA OF FLOW PROPERTIES
Angle of Compressibility
S. No Flow properties Hausner’sratio
repose(θ) Index (%)
1. Excellent 25-30 <10 1.00-1.11
2. Good 31-35 11-15 1.12-1.18
3. Fair 36-40 16-20 1.19-1.25
4. Passable 41-45 21-25 1.26-1.34
5. Poor 46-55 26-31 1.35-1.45
6. Very poor 56-65 32-37 1.46-1.59
7. Very very poor > 66 >38 >1.6
5.5.1. Evaluation of tablets
The quantitative evaluation and assessment of a tablets chemical, physical and
bioavailability properties are important in the design of tablets and to monitor product
quality. There are various standards that have been set in the various pharmacopeias
regarding the quality of pharmaceutical tablets. These include the diameter, size,
shape, thickness, weight, hardness, Friability and in-vitro dissolution characters.
5.5.2. Hardness
The hardness of the tablet was determined by using the Monsanto hardness
tester. The lower plunger was placed in contact with the tablet and a zero reading was
taken. The plunger was then forced against a spring by turning a threaded bolt until
the tablet fractured. As the spring was compressed a pointer rides along a gauge in the
barrel to indicate the force.47
73
5.5.3. Thickness
Control of physical dimensions of the tablets such as size and thickness is
essential for consumer acceptance and tablet-tablet uniformity. The diameter size and
punch size of tablets depending on the die and punches selected for making the
tablets. The thickness of tablet is measured by Vernier Callipers scale. The thickness
of the tablet related to the tablet hardness and can be used an initial control parameter.
Tablet thickness should be controlled within a ±5%. In addition, the thickness must be
controlled to facilitate packaging.
5.5.4. Friability
Friction and shock are the forces that most often cause tablets to chip, cap or
break. The friability test is closely related to tablet hardness and designed to evaluate
the ability of the tablet to withstand abrasion in packaging, handling, and shipping. It
is usually measured by the use of the Roche friability.48
Method
A number of tablets are weighed and placed in the apparatus where they are
exposed to rolling and repeated shocks as they fall 6 inches in each turn within the
apparatus. After that rotate the drum at 100 revolutions, the tablets are weighed and
the weight compared with the initial weight. The loss due to abrasion is a measure of
the tablet friability. The value is expressed as a percentage. A maximum weight loss
of not more than 1% of the weight of the tablets being tested during the friability test
is considered generally acceptable and any broken or smashed tablets are not picked.
The percentage friability was determined by the formula:
% friability = (W1-W2) / W1 X 100
W1 = Weight of tablets before test
W2 = Weight of tablets after test
74
5.5.5. Drug content
Twenty tablets were selected randomly from each batch, weighed and made
into a fine powder. The quantity of powder equivalent to 30mg of sildenafil citrate
was dissolved in 100ml of 0.01NHCL buffer and the resultant solution was filtered
and filtrate obtained was suitably diluted with the Ph 3 0.01NHcl.sildenafil citrate
content was determined spectrometrically by measuring the absorbance at 290 nm
using Shimadzu UV1601 Double beam spectrophotometer. The test was carried out in
triplicate for all the formulations and the drug content was calculated and reported. 49
5.5.6. Wetting time:
Wetting time is closely related to the inner structure of the tablet and to the
hydrophilicity of the excipients. According to the following equation proposed by
washburn E.W (1921), the water penetration rate into the powder bed is proportional
to the pore radius and is affected by hydrophilicity of the powder.
Di/dt= rγcos θ/ (4ήl)
Where I is the length of penetration, r is the capillary radius is the surface
tension, ή is the liquid viscosity, t is the time, and θ is the time, and θ is the contact
angle. It is obvious that pore size becomes smaller and wetting time increase with an
increase in compression force or a decrease in porosity. A linear relationship exists
between wetting time and disintegration time. Thus wetting is important step for
disintegration process to place. A place tissues paper folded double was placed in
Petri dish .(internal diameter is 6.5cm)containing 6ml of water .the tablet was placed
on the paper ,and the time for complete wetting of the tablet was measured in the
seconds .the method was slightly modified by maintaining water at 370C.wetting time
was evaluated .50
75
5.5.7. Disintegration time:
The disintegration test is carried out in apparatus containing a basket rack
assembly with six glass tubes of 7.75cm in length and 2.15 mm in diameter, the
bottom of which Consists of a#10 mesh sieve. The basket is raised and lowered 28-32
times per minute in a medium of 900ml water which is maintained at 37±2°C. Six
tablets were placed in each of the tubes and the time required for completer passage of
tablet fragments through the mesh (#10) was considered as the disintegration time of
the tablet.49
5.5.8. Dissolution studies
5.5.9. In vitro dissolution studies for chewable tablet
In vitro, drug release studies were carried out using USP XXIV dissolution
apparatus type II, with 900ml of dissolution medium maintained at 37±1°C for an
hour, at 100 rpm, 0.01N HCl adjust (PH-3) was used as a dissolution medium. 5ml of
the sample was withdrawn at predetermined time intervals replacing with an equal
quantity of drug-free dissolution fluid. The samples withdrawn were filtered through a
0.45µ membrane filter, and drug release in each sample was analyzed after suitable
dilution by UV/Vis Spectrophotometer at 290nm.
5.6.1. STABILITY STUDIES OF THE TABLET
Stability of a formulation can be defined as the time from the date of
manufacture of the formulation until its chemical or biological activity is not less than
a predetermined level of labeled potency and its physical characteristics have not
changed appreciably or deleteriously.
Formulation and the development of a pharmaceutical product are not
complete without proper stability analysis, carried out on it to assess their physical
and chemical stability and the safety. The purpose of stability testing is to provide
76
evidence on how the quality of a drug substance of drug product varies with time.
Under the influence of a variety of environmental factors such as temperature,
humidity, and light enabling recommended storage conditions, re-tests periods and
shelf- lives.
Generally, the observation of the rate at which the product degrades under
normal room temperature requires a long time. To avoid the undesirable delay, the
principles of the accelerated stability studies are adapted.
The international conference on harmonization (ICH) guidelines titled
“Stability Testing of New Drug Substances and Product” describes the stability test
requirements for drug registrations application in the European Union, Japan, and the
USA. ICH specifies the length of study and storage Conditions.
Long-Term testing: 25±2◦C/60%±5% RH for 12 months.
Accelerated Testing: 40±2◦C/75%±5% RH for 3 months.
Stability studies for the present work carried out at 40◦C/75%RH for the
selected formulation (F5) for 3 months.
Method
The selective formulations stored at 40◦C/75%RH for 3 months and evaluated
for their physical appearance and drug content at a specified interval of time. and also
performed were in vitro dissolution studies.
77
CHAPTER 6
RESULT AND DISSCUSSION
6.1. Result and Discussion
6.1.1. Standard calibration curve of sildenafil citrate
6.1.2. Concentration and absorbance of sildenafil citrate in 0.01N Hcl
S.No Concentration[µg/ml] Absorbance at 290nm
1. 0 0
2. 50 0.317
3. 80 0.419
4. 100 0.599
5. 120 0.718
6. 150 0.901
78
Figure no.6.1. Standard calibration curve of Sildenafil citrate
0.9
0.8
0.7
Aborbance at 290nm
0.6
y = 0.006x + 0.008
R² = 0.9995
0.5
0.4
0.3
0.2
0.1
0
0 20 40 60 80 100 120 140 160
conc in µg/ml
79
Figure no .6.2. I R Spectra of Sildenafil citrate pure drug
Figure no .6.3. IR Spectra of Sildenafil citrate+ Dried calcium carbonate
Figure no.6.4.IR spectra of sildenafil citrate + calcium carbonate (oyster shell)
Figure no.6.5. I R spectra Sildenafil citrate+ pvp k 30
Figure no .6.6. I R Spectra of Sildenafil citrate+ crospovidone
Figure no.6.7. I R Spectra of Sildenafil citrate+ croscarmellose sodium
Figure no. 6.8. I R Spectra of Sildenafil citrate +aspartame
Figure no.6.9. I R Spectra of Sildenafil citrate + Aerosil
Figure no.6.10. Sildenafil citrate + blend
Table no.4.Sildenafil citrate pure drug peak
(wave 400- 600- 800- 1000- 1200- 1400- 1600- 2700 3000-
number 500 800 1000 1200 1400 1600 1800 - 3700
cm-1) 3000
Functiona NH (CH2) =CH AROMA CH3 CH3 =CH CH3 =CH

l group OH 4 C=C TIC AROMA AROMA C=C CH2 C=C
C=C AROMA PHENOL TIC TIC AROMA CH ≡CH
C≡C TIC ALCOHO PHENOL PHENO TIC C≡C
ARO L ALCOHO L AMINE AROMAT
MATI AMINE L ALCOH C=O IC
C AMINE OL PHENOL
NO2 AMINE ALCOHO
NO2 L
AMINE
Table no.5.Excipients peak
(wave number
1700-2000 1700-2000 2000-2500 2500-3000 3000-3100
cm-1)
Functional group ΞCH,CΞC
=CH,C=C =CH,C=C CN CH3 =CH,C=C
Aromatic Aromatic CH2 Aromatic
Amine Amine CH Alcohol
Ketone Ketone Phenols
Amines
89
Table no.6.sildeanfil citrate + blend
(wave 400- 600- 800- 1000- 1200- 1400- 1600- 2700- 3000 2000- 2500- 3000-
number 500 800 1000 1200 1400 1600 1800 33000 - 2500 3000 3200
cm-1) 3700
NH (CH2)4 =CH AROM CH3 CH3 =CH CH3 =CH ΞCH, CH3 =CH,C=
functional
group OH C=C C=C ATIC AROM AROM C=C CH2 ,C= CΞC CH2 C
C≡C ARO PHEN ATIC ATIC ARO CH C CN CH Aromatic
AROM MATI OL PHEN PHEN MATI Aro Alcohol
ATIC C ALCO OL OL C mati Phenols
HOL ALCO ALCO AMI c Amines
AMINE HOL HOL NE Ami
AMINE AMINE C=O ne
NO2 NO2 keto
ne
FT-IR on the selected formulation prepared with different excipients and
polymer combination. The spectrum peak point of the formulation were similar with
that of pure sildenafil citrate, it clear indicate that there are no excipients interaction.
90
Figure no.6.11 sildenafil citrate pure drug
Figure no.6.12 Moringa gum
Figure no.6.13 sildenafil citrate +Moringa gum
Figure no.6.14 sildenafil citrate + All excipients
Table no.7.Sildenafil citrate pure drug
(wave 400- 600-800 800- 1000-1200 1200-1400 1400-1600 1600- 2700- 3000-3700
number 500 1000 1800 3000
cm-1)
Functional NH (CH2)4 =CH Aromatic CH3 CH3 =CH CH3 =CH
groups OH C=C C=C Phenol Aromatic Aromatic C=C CH2 C=C
C≡C Aromatic Alcohol Phenol Phenol Aromatic CH ≡CH
Aromati Amine Alcohol Alcohol Amine C≡C
c Amine Amine C=O Aromatic
NO2 NO2 Phenol
Alcohol
Amine
Table no.8.Moringa gum
(wave number cm-1) 400-500 1200-1600 2300-2400 2800-3000 3700-4000
Functional NH CH3 ≡CH CH3 Phenol

Groups OH CH2
C=C Aromatic C≡C CH2 Alcohol
Phenol
Alcohol CN CH
Amine
NO2
Table no.9.Sildenafil citrate with moringa gum
(wave 400- 600-800 800- 1000-1200 1200- 1400-1800 2600-3000 3000-3400 3400-
number 600 1000 1400 3800
cm-1)
Function NH (CH2)4 =CH Aromatic CH3 CH3 CH3 CH Phenol
al OH C=C C=C Phenol Aromatic Aromatic CH2 C=C
Group C=C C≡C Aromati Alcohol Phenol Phenol CH Aromatic
Aromatic c Amine Alcohol Alcohol ≡C
Amine Amine C≡C
NO2 NO2 Phenol
=CH Amine
C=C
Aromatic
Amine
C=O
95
Table no.10.Sidenafil Citrate with blend
(wave 400- 600-800 800-1000 1000- 1200- 1400-1800 2700-3000 3000-3400

number 600 1200 1400
cm-1)
Functional NH (CH2)4 =CH Aromatic CH3 CH3 CH3 CH
Group OH C=C C=C Phenol Aromatic Aromatic CH2 C=C
C=C C≡C Aromatic Alcohol Phenol Phenol CH Aromatic
Aromatic Amine Alcohol Alcohol ≡C
Amine Amine C≡C
NO2 NO2 Phenol
=CH Amine
C=C
Aromatic
Amine
C=O
FT-IR of the formulation and different excipients were prepared with KBr disc
method. From the Figure 6.2 – 6.14 it was evident that the peak points of the
formulation were similar with that of pure sildenafil citrate, it clearly indicate that
there is no interaction of API with the excipients.
96
6.2. Evaluation of pre compression parameters for chewable tablet
Table no.11.pre-compression parameters for chewable tablet (direct
compression)
Tapped
Formulation Bulk density Compressibility Hausner’s Angle of
density
code (gm/ml) index (%) ratio repose
(gm/ml)
F1 0.568 0.693 18.90 1.22 25o.12′
F2 0.574 0.726 20.99 1.26 27o.31′
F3 0.558 0.680 17.94 1.21 29o.46′
F4 0.574 0.765 24.96 1.33 25o.71′
F5 0.558 0.680 17.94 1.21 23o.86′
F6 0.562 0.685 17.95 1.21 24o.71′
F7 0.554 0.710 21.97 1.28 25o.10′
F8 0.574 0.735 21.90 1.28 28o.14′
F9 0.562 0.702 20.00 1.26 28o.14′
6.2.1. Angle of repose.
All the formulation prepared by direct compression method showed the angle
of repose between 25o and 29o excellent flow property it show in the above table.
6.2.2. Bulk density, tapped density, compressibility index and hausner’s ratio.
The results of , Bulk density, tapped density, compressibility index and
hausner’s ratio are shown in the table no. 11.The bulk density and tapped bulk density
for all formulation varied from 0.554 gm/cm3 to 0.574 gm/cm3 respectively. Tapped
density for all formulation varied from 0.680 to 0.735 gm/cm3. The result of Carr’s
consolidation index or (%) compressibility index for the entire formulation blend
97
ranged from 17 to 22 shows excellent compressibility index and hausner’s ratio for all
formulation varied from 1.21 to 1.33 which is an indicative of good flow property.
6.3. Post compression parameters
Table no.12.post compression evaluation parameters of chewable tablets
Wetti %
disintegratio
Formulation Average Hardness Thickness Friability ng Drug
n time
code weight (kg/cm3) (mm) time content
(sec)
(sec)
F1 701 5.68 5.18 0.134 90 60 99.2
F2 699 6.04 5.07 0.123 80 55 97.4
F3 700 5.54 5.22 0.093 65 50 99.6
F4 698 4.32 5.26 0.084 60 52 98.4
F5 700 4.10 5.17 0.124 40 45 99.3
F6 699 3.79 5.29 0.171 45 65 99.2
F7 698 3.05 5.20 0.138 70 59 100.1
F8 700 3.23 5.27 0.237 60 56 99.6
F9 698 3.38 5.31 0.264 78 50 99.6
6.3.1. Post-compression evaluation of Sildenafil citrate
Average weight, Hardness test, Thickness test, Friability, Disintegration time,
wetting time, Drug content.
The results of , Average weight,Hardness,Thickness,Friability,Disintegration
time, wetting time ,Drug content are shown in the table no. 12.The bulk density and
tapped density for all formulation varied from 698mg to 701 mg . All the
formulations passed the weight variation test as results were found to be IP limits of
±5% weight. The maximum thickness of the formulation was found to be 5.29 ± 0.005
mm in batch F6 and minimum thickness of the was found to be 5.07 ± 0.001 mm in
batch F2. The hardness of all the formulation tablets were determined by Pfizer
98
hardness tester and it was found to be in the range of 3.05 ± 0.01 to 6.04 kg/cm3.
Friability of the various batches was found to be in between 0.264 ± 0.14% to 0.084
%. Wetting time for all formulated tablet were found to be in the range of 40.01 ±
0.056 to 90.0 ± 0.56 seconds. The wetting time for tablets closely relate to the pore
size of the internal structure, which affects the penetration of water into the tablets.
The maximum percentage of the drug content of the formulation was found to be
100.1 ± 0.33 and maximum percentage of the drug content from all formulation was
found 98.4 ± 0.46, ensuring the uniformity of the drug content in the all formulations.
Figure no 6.15 wetting time for sildenafil citrate F5
Sildenafil citrate tablets after 5 seconds

Figure no 6.16 wetting time for Sildenafil citrate F5
Figure 6.17 wetting time for sildenafil citrate F5

Figure no 6.18 wetting time for sildenafil citrate F5

6.4. Dissolution data for chewable tablet
Table no.13. Dissolution data of chewable tablets
Time
in F1 F2 F3 F4 F5 F6 F7 F8 F9
min
5 15.65 16.32 18.35 14.06 20.48 17.48 12.48 11.79 8.69
10 18.28 19.62 22.35 26.50 37.49 20.68 29.68 24.69 11.49
15 25.45 29.40 34.45 38.56 60.67 30.78 45.78 50.48 50.87
20 40.67 43.67 48.87 44.96 78.48 50.78 60.68 65.67 76.79
25 60.70 64.68 69.89 74.74 90.79 79.40 88.48 78.45 88.48
30 70.89 85.78 88.98 90.25 100.5 89.45 98.48 97.65 95.67
Figure no 6.19 Dissolution Profile
120
110
100 F1
90
F2
80
cumulative%drug
70 F3
release
60 F4
50 F5
40 F6
30
F7
20
F8
10
0 F9
0 5 10 15 20 25 30
Time in Minuties
102
6.5. Dissolution graph for chewable tablet
All the formulations except batch F5 were not able to release 100 % of drug
within 30 minutes. F5 formulation released the total drug within 30 minutes which
will aid in the fast onset of action. This may be attributed to the presence of super
disintegrants croscarmellose sodium and crospovidone in batch F5. This also might
have increased by the increased wetting of the tablet resulting in fast dissolution.
6.5.1 Comparison of optimized formulation (f5) with innovator product (Viagra
100mg by marketed tablet)
The optimized formulation (F5) was compared with innovator product, Viagra
100mg for in-vitro disintegration and dissolution studies. The in-vitro disintegration
time of F5 formulation was found to be 40 seconds and that of Viagra was found to be
80 seconds. The in-vitro disintegration time of optimized formulation was found 6
times lesser than the innovator product. The dissolution time of F5 was found to be
100.5% in 30 minutes, where as the marketed product showed 98.08 % of drug
release in 30 minutes. This indicates formulation F5 showed rapid release of the drug
than the innovator product.
Table no.14. Comparison of formulation tablet vs marketed tablet
CUMULATIVE % DRUG RELEASE
FORMULATION 0min 5min 10min 15min 20min 25min 30min
F5 0 20.48 37.49 60.67 78.48 90.79 100.5
Viagra 0 16.67 30.76 58.78 70.54 86.78 98.08
103
120
110
100
90
cumulative%drug release 80
70
60
F5
50
VIAGRA
40
30
20
10
0
0 5 10 15 20 25 30
Time in Minuties
Figure no 6.20. Comparison of marketed tablet vs. sildenafil citrate F5 batch
6.5.2. Stability studies
Evaluation of tablet parameters after stability studies at storage condition-
400C/75%RH Period-3Month
Table no.15. Stability studies
S.no. Parameter Time duration

0Month 1Month 2Month 3Month
Physical
1 -- -- -- --
character
2 Friability% 0.42 0.45 0.45 0.42
3 Hardness[kg/cm3] 6.85 6.81 6.82 6.84
% drug release of
4 100.5 100.25 99.04 98.12
at 30min
104
6.5.3. Evaluation of pre compression parameters for batches with moringa gum
by wet granulation method.
Table no.16.pre-compression parameters for chewable tablet (wet granulation
method)
Bulk Tapped Angle

Formulation Compressibility Hausner’s
density density of
code index (%) ratio
(gm/ml) (gm/ml) repose
F10 0.558 0.685 17.94 1.21 26o.12′
F11 0.554 0.680 18.90 1.33 27o.71′
F12 0.560 0.726 21.90 1.28 29o.46′
6.5.4. Angle of repose.
All the formulation prepared by wet granulation method showed the angle of
repose between 26o and 29o revealing excellent flow property as shown in the table
no 16.
6.5.5. Bulk density, tapped density, compressibility index and hausner’s ratio.
The results of, Bulk density, tapped density, compressibility index and
hausner’s ratio of batches prepared by wet granulation method are shown in the table
no. 16. The bulk density and tapped bulk density of the formulation varied from 0.554
gm/cm3 to 0.560 gm/cm3 respectively. Tapped density for all formulation varied from
0.680 gm/cm3 to 0.726 gm/cm3. The result of Carr’s consolidation index or (%)
compressibility index for the entire formulation blend ranged from 17 to 21 shows
excellent compressibility index and hausner’s ratio for all formulation varied from
1.21 to 1.33 result in good flow properties.
105
6.5.6. Post compression parameters
Table no.17. Post compression evaluation parameters
Wetting
Formulatio Thickness Disintegration time (sec) %Drug
Avg. Hardness Friability
n (mm) time content
Weight (kg/cm2)
Code (sec)
F10 701 4.85 4.28 0.026 35 55 99.48
F11 699 4.81 4.41 0.021 25 58 97.56
F12 700 6.80 4.32 0.022 20 45 95.46
6.5.7. Post-compression evaluation of Sildenafil citrate
Average weight, Hardness test, Thickness test, Friability, Disintegration time,
Wetting time, Drug content.
The results of, Average weight, Hardness, Thickness, Friability, Disintegration
time, wetting time ,Drug content are shown in the table no.17. The average weight of
the tablet varies from 699 mg to 701mg. All the formulation passed the weight
variation test as results were found to be IP limits of ±5% weight. The maximum
thickness of the formulation was found to F10 batch 4.28 ± 0.005 mm minimum
thickness of the batch F11 was found to be 4.41±0.001mm F11.The hardness of all
the formulation tablets were determined by Pfizer hardness tester and it was found to
be in the range to be in the range of 4.80 ± 0.01 to 6.04kg/cm3.The Friability of the all
formulation tablet were determined by Roche friabiliators found to be in between
0.021±0.14% to 0.026%. Wetting time for all formulated tablet were found to be in
the range of 0.50±0.056 to 0.38±0.56 minuties. The wetting time for tablets closely
releated to the pore size of the internal structure .which is affected the penetration of
water into the tablets. The maximum percentage of the drug content of the
formulation was found to be 99.48±0.33 and maximum percentage of the drug content
106
from all formulation was found 95.46±0.46, ensuring the uniformity of the drug
content in the all formulations.
Figure no.6.21.Wetting time for sildenafil citrate F12
Wetting time for Sildenafil citrate 20seconds
Wetting time for sildenafil citrate 30 seconds

Wetting time for sildenafil citrate 45 seconds
6.6. Dissolution data for sildenafil citrate
Table no.18. Dissolution data of sildenafil citrate
TIME IN MIN F10 F11 F12
5 10.54 15.45 20.65
10 25.54 30.65 38.46
15 45.01 50.84 69.01
20 75.65 78.45 82.98
25 85.78 90.05 95.78
30 95.09 98.05 100.98

120
110
100
90
cumulative%drug release 80
70
60 F10
50 F11
40 F12
30
20
10
0
0 5 10 15 20 25 30
Time in minuties
Figure no .6.24 Dissolution profile
6.7. Dissolution graph for Wet granulation method for sildenafil citrate
The batch F12 released 100 % of the drug within 30 minutes. Hence
increasing the concentration of moringa gum resulted in the reduction of
disintegration time and increase of dissolution and wetting time. Hence moringa gum
can be suitably used with sildenafil citrate as a disintegrating agent for increasing the
onset of action.
109
Table no.19. Comparison of formulation tablet vs marketed tablet
CUMULATIVE % DRUG RELEASE
FORMULATION 0min 5min 10min 15min 20min 25min 30min
F12 0 20.65 38.46 69.01 80.98 91.78 100.98
Sildenafil citrate 0 18.02 35.67 62.03 77.04 80.43 95.08
120
100
cumulative %drug release
80
60
F12
Sildenafil citrate
40
20
0
0 5 10 15 20 25 30
Time in Minuties
Figure no.6.25. Comparison of marketed tablet vs Sildenafil citrate
110
6.8. Comparison of Optimized formulation (F12) with Innovator Product
(Sildenafil citrate 100mg by marketed tablet)
The optimized formulation (F12) was compared with innovator product,
Viagra 100mg for in-vitro disintegration and dissolution studies. The in-vitro
disintegration time of F12 formulation was found to be 20 seconds and that of Viagra
was found to be 80 seconds. The in-vitro disintegration time of optimized formulation
was found 6 times lesser than the innovator product. The dissolution time of F12 was
found to be 100.98 in 30 minutes, where as the marketed product showed 95.08 % of
drug release in 30 minutes. This indicates formulation F12 showed rapid release of the
drug than the innovator product.
111
CHAPTER 7
SUMMARY AND CONCLUSION
7.1. SUMMARY AND CONCLUSION
• The chewable tablets of taste masked sildenafil citrate were successfully prepared
by direct compression method and wet granulation method.
• 12 batches using various additives were prepared and evaluated with an aim of
presenting sildenafil citrate taste masked by the chewable tablet.
• Drug excipient compatibility study was performed by FTIR.
• The unpleasant taste of the sildenafil citrate was masked by intra-granular
addition of dried calcium carbonate, calcium carbonate from oyster shell and the
extra-granular addition of sweeteners and flavoring agents. Taste masking study
was done by using alkalizing agent in different ratio. Sildenafil citrate taste
masking was increased when dried calcium carbonate quantity was increased
because of reduction of the solubility of sildenafil citrate. Oyster shell calcium
carbonate when added to the drug did not masked the taste due to the gritty
nature of it.
• F5 batch showed less bitterness, low disintegration time and fast dissolution time
and hence was taken further comparing with the innovator drug.
• In the present study disintegrating properties of Moringa Oleifera gum powder
had been studied in comparison with other commercially available super
disintegrants. The isolated natural disintegrant exhibits faster drug dissolution
and disintegration. The isolated gum powder can be effectively used as
disintegrant for sildenafil citrate with the added advantage of the folkloric
aphrodisiac activity of it.
• The physicochemical evaluation results for the powdered blend of all trials pass
the official limits in the angle of repose, compressibility index, Bulk density,
Tapped density, Hausner’s ratio.
112
• Hence it may be summarized that the tablets prepared by direct compression
method might be a perfect and effective formulation to prevent the side effects in
treating erectile dysfunction”.
113
CHAPTER 8
BIBLIOGRAPHY
8. BIBLIOGRAPHY
1. Mukherjee, Biswaj, Arnalesh Samanta, and Subas Chandra Dinda. "Gum Odina—a
new tablet binder." Trends in Applied Sciences Research 1.4 (2006): 309-316.
2. Deveswaran, R., et al. "Evaluation of disintegrant properties of Plantago ovata
mucilage in comparison with other superdisintegrants." Arch Pharm Sci & Res 2.3
(2010).
3. Patel, D. M., D. G. Prajapati, and N. M. Patel. "Seed mucilage from Ocimum
americanum linn. as disintegrant in tablets: separation and evaluation." Indian journal
of pharmaceutical sciences 69.3 (2007): 431.
4. Gergely, Gerhard, Thomas Gergely, and Irmgard Gergely. "Lozenge or chewable
tablet." U.S. Patent No. 5,312,626. 17 May 1994.
5. Aulton`s Pharmaceutics, The design & manufacture of medicines,Biopharmaceutics
and pharmacokinetics, A Treatise, second edition, Valabh Prakashan, 315-384
6. Indian Pharmacopoeia. Vol. II, 4th ed. The Controller of Publications, New
Delhi,1996, p736
7. AM Raggi; R Mandrioli; A Ferranti; J. Pharm. Biomed. Analysis., 2003, 32, 1037-
1044.
8. J Siepmann; H Kranz; R Bodmeier; NA Peppas; Pharm Res., 1999, 16, 1748-1756.
9. Patil, J., V. Vishwajith, and V. Gopal. "Formulation development and evaluation of
chewable tablets containing non-sedating antihistamine." J. Pharm. Sci. Innov 1
(2012): 112-117.
10. Serajuddin, Abu. "Solid dispersion of poorly water‐soluble drugs: Early promises,
subsequent problems, and recent breakthroughs." Journal of pharmaceutical sciences
88.10 (1999): 1058-1066.
114
11. Udaykumar, M., et al. "Fast dissolving Tablets: New-fangled Drug Delivery System
A Comprehensive Review." International Journal of Research in Drug Delivery 2.3
(2012): 15-25.
12. Patel, Y., et al. "Chewing Gum as a drug delivery system." International Journal of
Pharmaceutical Sciences and Research 2.4 (2011): 748.
13. Renu, Jyoti Dahiya, Pawan Jalwal, and Balvinder Singh. "Chewable Tablets: A
Comprehensive Review." PharmaInnov J 4 (2015): 100-105.
14. Drug Dosage Form II (PHR312), Advantages of chewable tablets, Lecture 6, Pharos
University Alexandria, Nov .2011.
15. Drug Dosage Form II (PHR312), Advantages of chewable tablets, Lecture 7, Pharos
University Alexandria, Nov 2011.
16. Solanki, Himanshu K., et al. "Recent advances in granulation technology."
International Journal of Pharmaceutical Sciences Review and Research 5.3 (2010):
48-54.
17. Gupta, Surbhi, et al. "Industrial Process validation of tablet dosage form: An
overview." International Research Journal of Pharmacy 3 (2012): 48-54.
18. Ray, Chanda, Vandana Arora, and Vikas Sharma. "Fast dissolving tablets: a novel
drug delivery system for pediatric and geriatric patient." International bulletin of drug
research 1.2 (2011): 55-70.
19. Tripathi, Aditi, et al. "Taste masking: a novel approach for bitter and obnoxious
drugs." JPSBR 1.3 (2011): 36-142.
20. Wagh, Vijay D., and Shyam V. Ghadlinge. "Taste masking methods and techniques in
oral pharmaceuticals: current perspectives." Journal of Pharmacy Research Vol 2.6
(2009).
115
21. Dhakane, K. G., et al. "A novel approach for taste masking techniques and evaluation
in pharmaceutical: An updated review." Asian J Bio Pharm Sci 1 (2011): 18-25.
22. Gupta, A. K., et al. "Practical approaches for taste masking of bitter drug: a review."
International journal of drug delivery technology 2.2 (2010): 56-61.
23. Wadhwa, Jyoti, and Sidharth Puri. "Taste masking: A novel approach for bitter and
obnoxious drugs." International Journal of Biopharmaceutical and Toxicological
Research 1.1 (2011): 47-60.
24. Jangde, Rajendra Kumar. SECTION–‘C’BIO DATA OF INVESTIGATOR. Diss.
institute of pharmaceutical sciences, Guru Ghasidas University, 2000.
25. PHARMACEUTICALS: A REVIEW, International Journal of Pharma Research and
Development – Online /2010/PUB/ARTI/VOV-2/ISSUE7/SEP/008.
drugs." JPSBR 1.3 (2011): 36-142.
27. Boolell, Mitradev, et al. "Sildenafil: an orally active type 5 cyclic GMP-specific
phosphodiesterase inhibitor for the treatment of penile erectile dysfunction."
International journal of impotence research 8.2 (1996): 47-52.
28. Allen, L. V. "Featured excipient: capsule and tablet diluents." International Journal of
Pharmaceutical Compounding 4 (2000): 306-312.
29. Lehrman, G.P. and Skauers, D.M., "A comparative study of polyvinylpyrrolidone and
other binding agents in tablet formulations." Drug Stand., v. 26, 170-175 (1958).
30. Kornblum, Saul S., and Samuel B. Stoopak. "A new tablet disintegrating agent:
Cross‐linked polyvinylpyrrolidone." Journal of pharmaceutical sciences 62.1 (1973):
43-49.
116
31. Gordon, Marc S., and Zakauddin T. Chowhan. "Effect of tablet solubility and
hygroscopicity on disintegrant efficiency in direct compression tablets in terms of
dissolution." Journal of pharmaceutical sciences 76.12 (1987): 907-909.
32. Zhao, Na, and Larry L. Augsburger. "The influence of swelling capacity of
superdisintegrants in different pH media on the dissolution of hydrochlorothiazide
from directly compressed tablets." AAPS pharmscitech 6.1 (2005): E120-E126.
33. Prankerd, R. J., et al. "Degradation of aspartame in acidic aqueous media and its
stabilization by complexation with cyclodextrins or modified cyclodextrins."
International journal of pharmaceutics 88.1-3 (1992): 189-199.
34. Joint, F. A. O., WHO Expert Committee on Food Additives, and World Health
Organization. "Evaluation of certain food additives and contaminants: thirty-third
report of the Joint FA." (1989).
35. Daoust, R. G., and M. J. Lynch. "Mannitol in chewable tablets." Drug Cosmet Ind
93.1 (1963): 26-28.
36. Steckel, Hartwig, and Nina Bolzen. "Alternative sugars as potential carriers for dry
powder inhalations." International journal of pharmaceutics 270.1 (2004):
37. York, Peter. "Application of powder failure testing equipment in assessing effect of
glidants on flowability of cohesive pharmaceutical powders." Journal of
pharmaceutical sciences 64.7 (1975): 1216-1221.
38. Tukker, J. J., and C. J. De Blaey. "The addition of colloidal silicium dioxide to
suspension suppositories. II: The impact on in vitro release and bioavailability." Acta
pharmaceutica technologica 30.2 (1984): 155-160.
39. Dawoodbhai, Shabbir, and Christopher T. Rhodes. "Pharmaceutical and cosmetic uses
of talc." Drug development and industrial pharmacy 16.16 (1990): 2409-2429.
117
40. Chowhan, Zak T. "Harmonization of excipient standards." Drugs and the
pharmaceutical sciences 103 (2000): 321-354.
41. Nykänen, P., et al. "Citric acid as a pH-regulating additive in granules and the tablet
matrix in enteric-coated formulations for colon-specific drug delivery." Die
Pharmazie-An International Journal of Pharmaceutical Sciences 59.4 (2004):
268-273.
42. Todo, Hiroaki, et al. "Improvement of stability and absorbability of dry insulin
powder for inhalation by powder-combination technique." International journal of
pharmaceutics 271.1 (2004): 41-52.
43. Chowhan, Zak T. "Harmonization of excipient standards." Drugs and the
pharmaceutical sciences 103 (2000): 321-354.
44. Mashru, R. C., and S. V. Saikumar. "Development and validation of spectroscopic
methods for simultaneous estimation and dissolution of ofloxacin and ornidazole in
tablet dosage forms." Eclética Química 35.3 (2010): 123-132.
45. Prasad, Sree Giri B., Pradip Das, and Raghu CVS Kiran. "Formulation and evaluation
of chewable tablets of montelukast." Indian Journal of Research in Pharmacy and
Biotechnology 1.1 (2013): 29.
46. Devkota, Laxman, Bhupendra Kumar Poudel, and Junu Khatri Silwal. "Formulation
and in-vitro evaluation of chewable tablets of montelukast sodium." Cellulose 172.5
(2014): 3.
47. Anusha, V., et al. "Formulation and characterization of albendazole chewable
tablets." Der pharmacia sinica 3.2 (2012): 211-216.
48. Khokra, S. L., et al. "Formulation development and evaluation of chewable tablet of
albendazole by different techniques." Int J Pharm Pharm Sci 4.1 (2012): 461-464.
118
49. Patil, J., V. Vishwajith, and V. Gopal. "Formulation development and evaluation of
chewable tablets containing non-sedating antihistamine." J. Pharm. Sci. Innov 1
(2012): 112-117.
50. Anusha, V., et al. "Formulation and characterization of albendazole chewable tablets."
Der pharmacia sinica 3.2 (2012): 211-216.
51. Prakash, Indra, et al. "Formulation and In Vitro Bioequivalence Study of Amoxycillin
& Potassium Clavulanate Fast Dispersible Tablet." PharmaTutor 2.11 (2014):
102-111.
52. Sharma, Kuchi Shishir Chandra, Y. Kranthi Kumar, and Kondeti Ranjith Reddy.
"EFFECT OF DRUG RELEASE ON ALBENDAZOLE CHEWABLE TABLETS
BY USING DIFFERENT FORMULATION TECHNIQUES." International Journal
of Pharmaceutical Sciences and Research 5.10 (2014): 4543.
53. Jagdale, Swati. "Formulation and evaluation of chewable tablet of levamisole."
International Journal of Research in Pharmaceutical Sciences 1.3 (2016): 282-289.
54. Rao, Monica RP, and Rohini C. Bhingole. "Nanosponge-based pediatric-controlled
release dry suspension of Gabapentin for reconstitution." Drug development and
industrial pharmacy 41.12 (2015): 2029-2036.
55. Bhusnure, O. G., et al. "FORMULATION STRATEGIES FOR TASTE-MASKING
OF CHEWABLE TABLETS." American Journal of Pharmaceutical Research 5.12
(2015).
56. Sohi, Harmik, Yasmin Sultana, and Roop K. Khar. "Taste masking technologies in
oral pharmaceuticals: recent developments and approaches." Drug development and
industrial pharmacy 30.5 (2004): 429-448.
119
57. Vummaneni, Vishnumurthy, and Dheeraj Nagpal. "Taste masking technologies: an
overview and recent updates." International Journal of Research in Pharmaceutical
and Biomedical Sciences 3.2 (2012): 510-525.
58. Deshmukh, Basim, Kantilal Narkhede, and Pritam Chaudhari. "Formulation and In
Vitro Evaluation of Fast Dissolving Tablet Containing Sildenafil Citrate
Nanocrystals." Int. J. Pharma Res. & Rev 3 (2014): 10-18.
drugs." JPSBR 1.3 (2011): 36-142.
60. Rushiraj jani,Dasharath patel, et al.”Design and evaluation of sildenafil citrate fast
dissolving film for treatment of erectile dysfunction”.journal of chemical and
pharmaceutical Research, 2016, 8(8):877-891.
61. Patel, H., et al. "Formulation and evaluation of transdermal gel of sildenafil citrate."
Int J Pharm Res Allied Sci 1 (2012): 103-18.
62. Ahire, S. B., et al. "A REVIEW: TASTE MASKING TECHNIQUES IN
PHARMACEUTICALS." Pharma Science Monitor 3.3 (2012).
120

261510402sasikumar R

Uploaded by

Copyright:

Available Formats

261510402sasikumar R

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

261510402sasikumar R

Uploaded by

Copyright:

Available Formats

FORMULATION DEVELOPMENT AND EVALUATION OF TASTE

MASKED CHEWABLE TABLET 0F SILDENAFIL CITRATE

THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY,

In partial fulfillment of the requirements for the award of the degree of

Under the guidance of

This is to certify that the investigation described in the dissertation entitled

“FORMULATION DEVELOPMENT AND EVALUATION OF TASTE

MASKED CHEWABLE TABLET OF SILDENAFIL CITRATE” submitted by

Reg.No:261510402 was carried out in the Department of Pharmaceutics, Arulmigu

Kalasalingam College of Pharmacy, Anand Nagar, Krishnankoil-626 126, which

supervision and guidance of Mr.V.Sivakumar M.Pharm.,(Ph.D) Associate

Professor, Department of Pharmaceutics for the partial fulfillment of degree of

MASTER OF PHARMACY in PHARMACEUTICS.

Place: Krishnankoil Dr.N.Venkateshan. M.Pharm., PhD.,

This is to certify that this investigation described in the dissertation entitled

“FORMULATION DEVELOPMENT AND EVALUATION OF TASTE

MASKED CHEWABLE TABLET OF SILDENAFIL CITRATE ” submitted by

Reg.No:261510402 was carried out in the Department of Pharmaceutics, Arulmigu

Kalasalingam College of Pharmacy, Anand Nagar, Krishnankoil-626 126, which

supervision and guidance for the partial fulfillment of degree of MASTER OF

Place: Krishnankoil Mr.V.Sivakumar M.Pharm., (Ph.D)

“FORMULATION DEVELOPMENT AND EVALUATION OF TASTE

MASKED CHEWABLE TABLET OF SILDENAFIL CITRATE” submitted by

Reg.No:261510402 to The Tamil Nadu Dr. M.G.R. Medical University, Chennai, in

partial fulfillment of the requirements for the award of degree of MASTER OF

PHARMACY in PHARMACEUTICS was evaluated by,

“TALENT AND CAPABILITIES ARE OF COURSE NECESSARY BUT

I would like to express our thanks to the founder of our institution

I take a step forward to express my deep regards to Dr.N.Venkateshan

I express my gratitude to my guide Associate. Prof. Mr.V.Sivakumar.

I warmly acknowledge Mr.M.Murugan, M.Pharm, Department of

I express my gratitude to Dr.J. Jeya Anandhi M.Pharm., Ph.D., Head of the

My humble thanks to Dr.S.R.S.Senthilkuamr, M.Pharm.Ph.D., Department

S.NO Abbreviations Expanded Terminology

CHAPTER TITLE PAGE

3. AIM AND OBJECTIVE & PLAN OF WORK 35

6. RESULT AND DISSCUSSION 78

7. SUMMARY AND CONCLUSION 112

1.ORAL SOLID DOSAGE FORMS

the pharmaceutical company asks whether the drug is successfully administered by

oral route or not. As a natural defence mechanism to prevent infection or dehydration

capsule, lotions, suspensions, syrups and ointments. Plant products serve as an

alternative to synthetic products because of its local accessibility, environment

ovata mucilage has been evaluated in fast disintegrating tablet.Ocimum americanum

route due to its manifold advantages including:

drug to show sufficient pharmacological action can be administered. In case of

is self administered by patient.

degradation when compared to liquid dosage forms4.

or more active ingredients and obtained by compressing uniform volumes of particles.

dosage, compactness, portability, blandness of taste and ease of administration].

The primary potential advantages of tablets are,

 The cost is lower of all oral dosage forms.

 They are the lightest and most compact of all.

 Product identification is potentially the simplest and cheapest, requiring no

additional processing steps when employing an embossed or monogrammed

disintegration is not excessively rapid.

 They lend themselves to certain special profile products, such as enteric or

delayed release products.